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ABSTRACT
NOVEL AMINO ACID TRANSPORTER-TARGETED RADIOTRACERS FOR
BREAST CANCER IMAGING

Publication No._______
FanLin Kong, Ph.D.
Supervisory Professor: David J. Yang, Ph.D.

Breast cancer is the most common malignancy among women in the world. Its
5-year survival rate ranges from 23.4% in patients with stage IV to 98% in stage I
disease, highlighting the importance of early detection and diagnosis.

18

F-2-Fluoro-

2-deoxy-glucose (18F-FDG), using positron emission tomography (PET), is the most
common functional imaging tool for breast cancer diagnosis currently. Unfortunately,
18

F-FDG-PET has several limitations such as poorly differentiating tumor tissues

from inflammatory and normal brain tissues. Therefore,

18

F-labeled amino acid-

based radiotracers have been reported as an alternative, which is based on the fact
that tumor cells uptake and consume more amino acids to sustain their uncontrolled
growth. Among those radiotracers,

18

F-labeled tyrosine and its derivatives have

shown high tumor uptake and great ability to differentiate tumor tissue from
inflammatory sites in brain tumors and squamous cell carcinoma. They enter the
tumor cells via L-type amino acid transporters (LAT), which were reported to be
highly expressed in many cancer cell lines and correlate positively with tumor

v

growth. Nevertheless, the low radiosynthesis yield and demand of an on-site
cyclotron limit the use of 18F-labeled tyrosine analogues.
In this study, four Technetium-99m (99mTc) labeled tyrosine/ AMT (α-methyl
tyrosine)-based radiotracers were successfully synthesized and evaluated for their
potentials in breast cancer imaging. In order to radiolabel tyrosine and AMT, the
chelators N,N’-ethylene-di-L-cysteine (EC) and 1,4,8,11-tetra-azacyclotetradecane
(N4 cyclam) were selected to coordinate 99mTc. These chelators have been reported
to provide stable chelation ability with

99m

Tc. By using the chelator technology, the

same target ligand could be labeled with different radioisotopes for various imaging
modalities for tumor diagnosis, or for internal radionuclide therapy in future.
Based on the in vitro and in vivo evaluation using the rat mammary tumor
models,

99m

Tc-EC-AMT is considered as the most suitable radiotracer for breast

cancer imaging overall, however,

99m

Tc-EC-Tyrosine will be more preferred for

differential diagnosis of tumor from inflammation.

vi
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CHAPTER 1 Introduction
I.

Breast cancer and its diagnosis
a.

Introduction
Breast cancer is the most common malignancy among women in the United

States. In 2010, a total of 207,090 new cases of invasive breast cancer, along with
54,010 new cases of non-invasive types, were expected to be diagnosed in women.
Moreover, about 39,840 women were projected to die from this disease in the same
year. According to the National Cancer Institute, the 5-year survival rate of breast
cancer ranges from 23.4% in patients with stage IV disease to 98% in patients with
stage I disease, highlighting the importance of early detection and diagnosis of
breast cancer[1].
Molecular imaging serves as an essential tool in breast cancer diagnosis and
staging, as well as provides a significant proportion of information for surgical
management, radiation planning, chemotherapeutic assessment, and treatment
response monitor of patients. In the present, positron emission tomography (PET),
single photon emission computed tomography (SPECT), and their combinations
with computed tomography (CT) or magnetic resonance imaging (MRI), are major
functional molecular imaging modalities used in clinic. PET and SPECT radiotracers
can target tumors based upon tumor-specific characteristics at molecular levels.
The accumulating understanding of the breast cancer molecular biology has
highlighted pivotal factors that are critical for breast cancer progression, which
allows researchers to select suitable targets for developing tumor-specific
radiotracers. For instance, given that sustained tumor growth demands elevated

1

glucose consumption for energy production in the lesion regions, PET radiotracer
18

F-labeled glucose analog

18

F-2-fluoro-2-deoxy-glucose (18F-FDG) has commonly

been used to visualize the glucose metabolism of breast cancer cells[2].

18

F-labeled

16α-17β-fluoroestradiol is used to image estrogen receptors, which are highly
overexpressed in a large proportion of breast tumor tissues[3]. Many other
radiotracers have been designed to image cell proliferation, cell apoptosis,
angiogenesis and hypoxia of breast tumors. Since breast cancer treatment has
become more individualized in compliance with the distinct biological characteristics
of tumors from each patient, the more target-specific molecular imaging radiotracers
may hold the key to guide treatment selection and evaluate treatment response in
the early stages.

b.

Positron emission tomography (PET) and its radionuclides
Positron emission tomography (PET) is a 3-D nuclear medicine imaging

technique, which is based on detecting the annihilation radiation emitted from a
certain positron-emitting radionuclide[2]. When the radionuclide decays, the positron
annihilates an electron nearby, thus creates two 511 keV photons emitted opposite
to each other (180 degree). This process is called “coincidence event”, which can
be observed by PET detectors arranged in an array of full or partial ring around the
patient body axis. Data are then reconstructed using standard algorithm. By using
this coincidence-detection method, the traditional collimator can be eliminated, and
therefore the spatial resolution and sensitivity can be highly improved.

2

Commonly used PET imaging radionuclides are listed in Table 1.1. In order to
monitor a small bioactive molecule in vivo without altering its chemical structure,
carbon-11 (11C) is often used as a label to substitute the stable carbon atom
that molecule. Given that

12

C in

11

C has a half-life of only 20 minutes which has less

commercial interest, fluorine-18 (18F) with a half-life of 110 minutes has been used
alternatively. In fact,

18

F is currently the most frequently used/developed PET

radionuclide. In addition to

11

C- and

short half-lived radiotracers such as

18

F-labeled biomarkers, there are some other

15

O-labeled water and

13

N-labeled ammonia

that measure blood flow in the patient body[4]. Moreover, copper-64 (64Cu) and
zirconium-89 (89Zr), because of their long half-life (12.7 h and 78.4 h, respectively),
have been increasingly recognized in the past decade for labeling nanoparticles or
slowly

localizing

antibodies[5].

Other

than

those

cyclotron-produced

PET

radionuclides mentioned above, generator-produced gallium-68 (68Ga) and
rubidium-82 (82Rb) have also shown high potentials in PET imaging. The advantage
of in-house generator produced radionuclides is that the generator itself serves as a
top-of-the-bench source for short half-lived radionuclides in the places that are
located far from the cyclotron facility. Besides, it is quite simple to access
radionuclides from the generator, and less expensive compared to cyclotronproduced radionuclides.

c.

PET-based radiotracers for breast cancer imaging in clinic
18

F-FDG, a glucose analogue, has become the most common and attractive

radiotracer for PET. Both

18

F-FDG and glucose are transported across the cell
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membrane by glucose transporters.

18

F-FDG is phosphorylated by hexokinase to

18

F-FDG-6-phosphate, whereas glucose is phosphorylated to glucose-6-phosphate.

Unlike glucose-6-phosphate,

18

F-FDG-6-phosphate cannot be further metabolized

and therefore is trapped and accumulated steadily in tumor cells[2]. Hence,

18

F-

FDG is able to provide high sensitivity for detecting, staging, and re-staging tumors
by imaging high glucose metabolic rates in tumor cells. For breast cancer cells,
increased glucose utilization is caused by the overexpression of the glucose
transporters Glut-1 and Glut-3 and by increased hexokinase activity[6]. The ratelimiting step in the uptake of

18

F-FDG in breast cancer appears to be the

phosphorylation process by hexokinase, particularly hexokinase I[6].
Although

18

F-FDG-PET generally has high sensitivity and specificity in

detecting malignancies, whole-body

18

F-FDG-PET is not quite suitable for primary

breast cancer diagnosis, especially for low-grade tumors and tumors smaller than 1
cm in diameter[7]. In addition, it is not appropriate to use
screening[8]. For locoregional staging of breast cancer,

18

F-FDG for breast cancer

18

F-FDG-PET has shown

high sensitivity in axillary staging of patients with late stage cancer, but it is not
sensitive enough in detecting early-stage micrometastases and small tumorinfiltrated axillary lymph nodes[9]. Nevertheless,

18

F-FDG-PET appears to be

suitable for distant (systemic) staging; it is also well suited for staging of locally
advanced breast cancer, which usually has a large primary tumor (>5 cm in
diameter) or advanced axillary disease without clinically apparent distant
metastases[10]. Moreover, several studies have demonstrated that

18

F-FDG-PET is

superior to traditional bone scintigraphy in the detection of osteolytic and
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intramedullary metastases but is inferior in the detection of primary osteoblastic
lesions[11]. An increasing number of studies have used
treatment responses. Although

18

F-FDG-PET to evaluate

18

F-FDG has not yet been recommended as a

routine assessment agent, accumulated

18

F-FDG uptake has been proven to be an

accurate early predictor of poor response to therapy. In a study showing that high
18

F-FDG uptake was associated with a low blood flow or perfusion rate in tumors,

the locally advanced breast cancer patients with high uptake were more likely to
have poor response and early relapse[12].
Given its low specificity, many radiotracers have been developed as an
alternative to18F-FDG. Table 1.2 summarizes the PET-based radiotracers that
currently applied for breast cancer imaging, according to the categories of the
tumor-specific targets to which they are aimed at.
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Table 1.1. Radionuclides commonly used in PET imaging.
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Table 1.2. PET-based radiotracers used to detect breast cancer in humans, by tumor-specific
target.

Target

PET Radiotracer

Perfusion

15 O-H

2O

18 F-FDG

Glucose metabolism

18 F-FES
18 F-fluorotamoxifen

Hormone receptor

21-[18F]fluoro-16α-ethyl-19-norprogesterone
16β-18F-fluoromoxestol

HER2

89Zr-trastuzumab

Cell proliferation

18 F-FLT
18 F-galacto-RGD
18 F-AH111585

Angiogenesis

89 Zr-bevacizumab
11C-methionine

Amino acid transporters and protein
synthesis

11 C-tyrosine

O-(2-[18F]fluoroethyl)-l-tyrosine
11 C-Iressa

Epidermal growth factor receptor

18 F-fluoromisonidazole
18 F-fluoroetanidazole

Hypoxia

18 F-fluoroazomycin-arabinoside
64 Cu-diacetyl-bis-N4-methylthiosemicarbazone
18 F-annexin V

Apoptosis

11 C-choline

Membrane synthesis

18 F-fluorocholine
18 F-fluoride

Bone
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d.

Planar scintigraphic imaging, single photon emission computed

tomography (SPECT) and their radionuclides
Planar scintigraphic imaging uses one gamma camera to capture and
determine gamma-ray emitting photons directly from the labeling radionuclide in a
particular angle. The energy of the radionuclide for planar scintigraphic imaging is
generally from 70 to 364 keV (Table 1.3).

Table 1.3. Radionuclides commonly used in SPECT imaging.

Emitted Photon Energy

Radionuclide

Decay Mode

Half-life

99mTc

IT

6.01 h

201Tl

EC

73.0 h

123I

EC

13.2 h

159 (83.3%)

131I

Β-

8.02 d

364 (81.2%)

111In

EC

67.4 h

171(90.3%), 245 (94%)

67Ga

EC

78.3 h

IT: isomeric transition
EC: electron capture
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[keV]

140 (87.7%)
71 (47%), 135 (3%), 167
(10%)

93 (37%), 184 (20.4%), 300
(16.6%)

Different from planar scintigraphic imaging, a typical single photon emission
computed tomography (SPECT) system consists of one or more rotating gamma
camera(s) to obtain multiple projection images from different views around the
patient, and a computer algorithm for 3D image reconstruction. A collimator is
required to collect the γ-ray photons that are emitted from the patient body only in a
particular direction[13].
Technetium-99m (99mTc, t1/2= 6.02 h) is the most common radionuclide for
planar and SPECT imaging. It emits a 140 keV gamma ray in 89% abundance,
which can be detected by NaI detectors. In addition, it is produced with in-house
generator that contains the parent nuclide molybdenum-99 (99Mo), and does not
require the cyclotron. Since the chemistry of diagnostic radionuclide

99m

Tc is very

similar to that of the therapeutic radioisotope rhenium-188 (188Re), they could be
labeled to the same ligand, which leads to the diagnostic/therapeutic matched
pair[14].
Although the resolution and sensitivity of SPECT is not as good as PET scan
due to its physical nature, SPECT and SPECT/CT still play important and
irreplaceable

roles

in

nuclear

imaging

area.

First

of

all,

SPECT

radiopharmaceuticals are comparatively easier and less costly to produce. In
addition, given that most SPECT radionuclides have longer half-life than that of PET
radionuclides, SPECT offers more possibility to broaden the observational time
window that allows the doctors to monitor biological processes in vivo several hours
or even days after radiopharmaceutical administration. Furthermore, only limited
facilities around the world can afford complete armamentarium of PET instruments

9

and cyclotron for the local production of short-lived positron-emitters. Clinical data
have shown that 15.9 million SPECT procedures were performed in 2007, while
only 1.6 million of PET procedures were performed, in comparison[15].

e.

Planar and SPECT-based radiotracers for breast cancer imaging in

clinic
To date, the most common radiotracer used for SPECT and planar
scintigraphic imaging such as scintimammography is 99mTc-methoxyisobutylisonitrile
(99mTc-MIBI or 99mTc-sestamibi). Scintimammography has been increasingly used to
assess the suspicious lesions of patients with a negative or indeterminate
mammography in the clinic[16]. This small lipophilic cation was originally developed
as a myocardial perfusion agent. The first report of its application in breast cancer
detection was by Aktolun et al. in 1992[17]. The cellular uptake mechanisms of
99m

Tc-sestamibi still remain unclear; however, its uptake is driven by a negative

transmembrane potential and most of the radioactivity is found in the
mitochondria[18].

99m

Tc-sestamibi scintimammography shows higher sensitivity

(85%) and specificity (87%) than the traditional mammography, and its sensitivity is
independent of breast density[19]. In addition,

99m

Tc-sestamibi is a substrate of the

transmembrane P-glycoprotein (Pgp), which is a member of the MDR/TAP
subfamily that is involved in the multidrug resistance. Therefore, the uptake,
clearance, and retention of

99m

Tc-sestamibi have been investigated as predictors of

response to chemotherapy in human breast cancer[20]. In a study of 45 patients
with primary breast cancer, Cayre et al concluded that a negative

10

99m

Tc-sestamibi

scintimammography predicted chemoresistance with a specificity of 100%. Besides,
99m

Tc-sestamibi uptake was inversely correlated to the expression of multidrug

resistance protein MDR1 (P<0.05) in invasive ductal carcinomas[21].
Nevertheless, 99mTc-sestamibi scintimammography demonstrates relatively low
sensitivity in detecting the nonpalpable lesions or tumors smaller than 1 cm[22].
Therefore, the high resolution small field-of-view breast-specific γ-imaging (BSGI)
has been developed as an alternative. Similar to positron emission mammography
(PEM), the single-head detector used in BSGI is mounted opposite to a
compression plate, so the patient’s breast is compressed between detector and
plate. According to a 6-year BSGI study performed by Hruska et al. at Mayo Clinic,
the sensitivity of BSGI for tumors larger than 1 cm was 97%, while that for tumors
smaller than 1 cm was 74%[23]. When comparing BSGI with PEM, although the
average sensitivity of PEM (93%) is slightly higher than that of BSGI (89%), BSGI
has a much higher negative predictive value (100%) than that of PEM (88%)[24].
Thus, both of the imaging modalities have great detection ability in existing studies,
and there is no proven clinically significant advantage to either modality over the
other so far.
Although not majorly used, several other radiotracers have been successfully
developed as alternatives to

99m

Tc-sestamibi. Table 1.4 summarizes the

radiotracers that currently applied to SPECT and planar scintigraphic imaging of
breast cancer, categorized according to the tumor-specific targets to which they are
aimed at.
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Table 1.4. Planar and SPECT-based radiotracers used to detect breast cancer in humans,
by tumor-specific target.

Target

SPECT or Gamma Imaging Radiotracer
Thallium-201
99mTc-sestamibi

Perfusion

99mTc-tetrofosmin

Glucose metabolism

99mTc-ethylenedicysteine-N-acetylglucosamine

Hormone receptor

123I-16α-estradiol

HER2

111In-trastuzumab
99mTc-NC100692

Angiogenesis

111In-bevacizumab
99mTc-methionine

Amino acid transporters and
protein synthesis

L-3-123I-α-methyltyrosine
99mTc-EC-annexin

Apoptosis
Somatostatin receptors

111In-diethylenetriamine

pentaacetic acid-octreotide

99mTc-MDP

Bone

67Ga-citrate
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V

II.
a.

Amino acid transporter systems
Introduction
Amino acids cross the cell membranes via various amino acid transporter

systems based on their structures. The mammalian amino acid transporter systems
can be classified as neutral, acidic or basic classes according to the substrates they
transport. Each of the classes can be further divided into Na+-dependent and Na+independent transporter subclasses[25]. To date, more than 20 systems have been
identified (Table 1.5), and the major systems that are present in all tissues are the
Na+-dependent system A and ASC, as well as the Na+-independent system L[26-28].
Transport of an amino acid generally depends on the difference between its intraand extra-cellular concentration, and is frequently associated with counter-transport
of a second amino acid, whose gradient is controlled by one or more of the Na+dependent systems.
In tumor cells, amino acid transporters are generally upregulated to facilitate
their increasing amino acid uptake[29, 30]. In addition to functioning as the basic
building blocks of proteins, amino acids are also important sources of carbon and
nitrogen in the synthesis of purine and pyrimidine nucleotides, amino sugars, and
glutathione, which are the essential elements for rapid proliferation of tumor
cells[31]. Therefore, the rate of amino acid uptake and transport, rather than the
protein synthesis rate, is very crucial for tumor cells[32, 33].
The development of amino acid-based imaging probes has focused on
radiolabeling the substrates of those amino acid transporter systems, especially for
system L and/or A given that they are the two major transport systems in
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mammalian cells. Here, we introduce systems A and L, their molecular biology and
transport mechanisms.

Table 1.5. Major amino acid transporter systems in mammalian.
Transporter System

Substrate

Transporter

Family

A

Ala, Pro, N-methyl amino acids

ATA1-3

SLC38

ASC

Ala, Ser, Thr, Cys, (Gln)

ASCT1,2

SLC1

B0

Broad substrate selectivity

Β-system

Β-Ala, Tau

Taut

SLC6

G

Gly, Sar

GLYT1,2

SLC6

N

Na+-dependent

Neutral

Gln, Asn, His

SN1,2

SLC38

y+L

Neutral and basic amino acids

y+LAT1·4F2hc, y+LAT2·4F2hc

SLC7

asc

Ala, Ser, Thr, Cys

Asc-1·4F2hc, Asc-2·?

SLC7

b0,+

Neutral and basic amino acids

BAT1/b0,+AT·rBAT

SLC7

L

Large neutral amino acids

LAT1-4·4F2hc,

SLC7

T

Aromatic amino acids

TAT1

SLC16
SLC6

Na+-independent

Na+-dependent

B0,+

Neutral and basic amino acids

ATB0,+

b0,+

Neutral and basic amino acids

BAT1/b0,+AT·rBAT

SLC7

y+

Basic amino acids

CAT1-4

SLC7

y+L

Neutral and basic amino acids

y+LAT1·4F2hc, y+LAT2·4F2hc

SLC7

Na+-dependent

X-AG

L-Glu, L-/D-Asp

EAAC1, GLT-1, GLAST, EAAT4,5

SLC1

Na+-independent

x -c

Cys/Glu exchange

xCT·4F2hc

SLC7

Basic
Na+-independent

Acidic

SLC: solute carrier family, a naming of transporter families by Human Gene
Nomenclature Committee.
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b.

System A
System A is a Na+-dependent system that transports small neutral aliphatic

amino acids. It can uniquely recognize and transport N-methylated amino acids, and
thus, N-methyl aminoisobutyric acid (MeAIB) is used as a system A specific inhibitor
to determine its substrates. It can also be characterized by tolerance of Li+
substitution for Na+, and by the property of trans-inhibition[34]. System A is pH
sensitive and displays hormonal and adaptive regulation[35]. It has three subtypes:
SNAT1 (the sodium-coupled neutral amino acid transporter 1), SNAT2, and SNAT4.
Some of these subtypes are considered to be associated with cancers. For instance,
Kondoh et al. demonstrated that SNAT1 mRNA expression in human hepatocellular
carcinoma (HCC) cell lines was significantly higher than that of normal liver tissue.
In addition, the expression of SNAT1 was significantly activated in HCC tissues as
well as in premalignant cirrhotic livers from HCC patients[36].

c.

System L
System L (L-type amino acid transporter system, or LAT) is a Na+-independent

system for transporting large neutral amino acids such as branched or aromatic
amino acids. It exchanges one amino acid from the extracellular compartment with
one amino acid from the intracellular compartment (Fig. 1.1). LAT has broad
substrate selectivity and four subtypes named LAT1-4, respectively. LAT1 and
LAT2 have similar structures and their amino acid sequences show 50% identity in
human. Both of them form heterodimeric complexes via a disulfide bond and
comprise of a 12-transmembrane catalytic light chain and a type-II glycoprotein
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heavy chain called 4F2hc (Fig. 1.1). Different from LAT1 and LAT2, the subtypes
LAT3 and LAT 4 can function without 4F2hc; however, since both of them were
identified recently, little is known about their molecular properties and functions.
Among four subtypes, only LAT1 shows increased transport activity and plays an
important role in proliferating cells such as placenta and tumor cells. LAT1
upregulation has been observed in various cancer types as well as tumor cell lines,
thus, is considered as a diagnostic and prognostic biomarker for cancers[37-40].
LAT1 transports not only amino acids, but also some hormones such as thyroxine
and triiodothyronine, as well as other drugs such as L-DOPA for Parkinson’s
disease

and

melphalan

for

cancer

treatment[41].

BCH

(2-amino-endo-

bicycloheptane-2-carboxylic acid), a specific inhibitor of LAT, is often used to
determine whether a certain compound like amino acid-based radiotracer is LAT
substrate[42].

16

Figure 1.1.. Predicted structure of L
L-type amino acid transporter LAT-1
1 and its transport
mechanism.
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III.

Tyrosine-based radiotracers for tumor imaging

a.

11

C-labled tyrosine analogue

Theoretically, all amino acids can be labeled with

11

C since all of them contain

at least two carbons (the carboxyl carbon and the α-carbon) that can serve as
labeling sites. Although

11

C is adequate for amino acid-based PET imaging, which

typically has peak tumor uptake 15-20 min after i.v. injection, the 20 min half-life of
11

C restricts its use only to the institutions that have an onsite cyclotron, and thus,

makes it clinically impractical[43].
L-[1-11C]-tyrosine (11C-Tyr) is a reliable amino acid-based PET probe for tumor
detection and quantification in multiple types of malignancies, including brain[44],
breast[45], head and neck cancers[46], and soft tissue sarcomas[47]. Since

11

C-Tyr

is largely incorporated into proteins, it has been used as an appropriate probe for
protein synthesis rate quantification. Same as its precursor tyrosine,

11

C-Tyr has

been proven to enter the tumor cells predominantly via amino acid transport system
L.
There are mainly three approaches to synthesize

11

C-Tyr: via the Bücherer-

Strecker reaction[48], an enzymatic route[49], and the robotic synthesis using
isocyanide method[50].

11

C-Tyr can be obtained within 50-60 min in a high purity

(>98%) through each method, however, the overall radiochemical yield by robotic
synthesis was relatively lower than the other two methods (10% vs. 40-60%).
Regardless of its low synthetic yield, the robotic synthesis is preferable because it is
a convenient procedure for routine

11

C-Tyr production and can avoid high dose

radiation exposure and contamination.

18

To date, many studies have been conducted to compare the imaging potentials
between 11C-Tyr and 18F-FDG. 11C-Tyr appears to be better than 18F-FDG for breast
cancer imaging because of its lower uptake in fibrocystic disease[45].

11

C-Tyr-PET

showed higher specificity (95% vs. 88%), accuracy (95% vs. 88%), and positive
predictive value (63% vs. 48%) than those of

18

F-FDG-PET in detecting cervical

lymph nodes of 11 patients with squamous cell carcinoma of the oral cavity[51].
Furthermore, prolactinomas could be clearly visualized by 11C-Tyr-PET, but not
FDG-PET[52]. Kole et al. compared

18

F-FDG and

18

F-

11

C-Tyr imaging potentials in

patients with soft-tissue tumors before and after chemotherapy and found out that
18

although

F-FDG had a better indication of tumor grade,

11

C-Tyr was more

accurate in predicting proliferation and mitotic rate of the tumor lesions, especially
after treatment[53]. In another study, Boer et al. have demonstrated a significant
positive relationship between high

11

C-Tyr uptake and poor survival rate of patients

with laryngeal carcinoma under radiotherapy[54]. However,

11

C-Tyr seems not

suitable for visualizing the tumors with a low proliferation rate such as testicular
nonseminoma germ-cell tumor[55].

b.

123

I-labeled tyrosine analogue

The SPECT radionuclide

123

I has a long half-life of 12.3 hr, which allows the

imaging of slower biological processes taking place over the course of 1-2 days.
3-[123I]iodo-α-methyl-L-tyrosine (123I-IMT) is a useful SPECT imaging probe for
diagnostic evaluation and therapy planning to patients with brain tumors[56]. It can
be synthesized by direct electrophilic iodination of α-methyl-L-tyrosine (AMT) in the
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presence of an oxidizing agent such as Chloramine-T[57] and Iodogen[58]. The
average radiochemical yield ranges from 60-80%.
123

I-IMT is dominantly transported by amino acid transport system L and not

incorporated into proteins. It is eliminated via renal clearance, and the highest
absorbed doses are observed in bladder, colon, and kidneys[59]. Although it was
not ideal to determine prognosis and grade of gliomas,

123

I-IMT-SPECT still

succeeds to image the extent of cerabral gliomas as well as their recurrences, and
to differentiate recurrences from radionecrosis[60-62]. For extracranial tumors,

123

I-

IMT-SPECT has been used to evaluate non-small cell lung cancer[63], head and
neck cancer[64], melanoma[65], and soft tissue sarcomas[66]; however, most of
those clinical results were similar or even inferior to those from

18

F-FDG-PET.

Plotkin et al. demonstrated that the positive predictive value in the diagnosis of
relapsed head and neck cancer could be improved by integrating low-dose CT with
123

I-IMT-SPECT[67, 68]. Therefore,

123

I-IMT applied with combined SPECT/CT

imaging is recommended for the future clinical studies.
Other than

123

I-IMT, iodine-125-labeled 3-[125I]iodo-α-methyl-L-tyrosine was

also synthesized and evaluated in vitro and in vivo[69-71], however, no clinical
study has been reported so far.

c.

18

F-labeled tyrosine analogues

Compared to

11

C with a 20 min short half-life,

18

F has a 109.8 min half-life and

thus can be remotely distributed to the institutions without an onsite cyclotron. An
increasing number of

18

F-labeled tyrosine analogues have been developed, and
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their transport mechanisms as well as potentials to image tumors have been
18

intensively under investigation. The three major

F-labeled tyrosine-based

radiotracers are discussed here.

L-2-[18F]fluorotyrosine (18F-Tyr)

1.

L-2-[18F]fluorotyrosine (18F-Tyr) was first evaluated as a PET tracer of cerebral
protein synthesis by Coenen et al in 1989[72]. The initial synthetic route is shown in
Fig. 1. 2a . Briefly, [18F]acetylhypofluorite is used for electrophilic radiofluorination of
O-acetyltyrosine in CF3COOH as solvent at 00C. After base-catalyzed hydrolysis of
the acetyl moiety, the final product

18

F-Tyr then can be isolated from the isomeric

mixture via reverse phase HPLC with a specific activity of 10-20 GBq/mmol in a 17%
yield[72]. Recently, Melean et al reported a new 3-step nucleophilic synthesis
procedure starting with [18F]fluoride, and the total synthetic yield of

18

F-Tyr was

optimized up to 49% (Fig. 1. 2b).

COOH
AcO

[18 F]AcOF

COOH
A cO

CF3COOH, 00 C

NH 2

18

F

COOH

OH-

HO
H2O, R.T.

NH2

18

F

NH2

Fig. 1. 2a. The initial synthetic scheme of L-[2-18F]Fluorotyrosine.

F

Boc
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Boc
N
O

BnO
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Boc
N

Rh (PP h3)3Cl

N

BnO

O

18
HCl

N

O

Fig. 1. 2b. The optimized synthetic scheme of L-[2-18F]Fluorotyrosine.
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HO

F

COOH
NH2

18

F-Tyr has been successfully used for detecting brain tumors[73]; however, it

appears to be less sensitive for staging non-small cell lung cancer and lymphomas
compared to 18F-FDG[74].

L-[3-18F]-α-methyl tyrosine (18F-FMT)

2.

Due to its lower physioligical uptake in cortex than that of

18

F-FDG, L-[3-18F]-α-

methyl tyrosine (18F-FMT) was initially studied as a brain tumor imaging agent for
PET by Inoue et al[75]. It was developed based on the same concept of its
iodinated SPECT counterpart

123

I-IMT, and hence, the metabolic behavior of

FMT appears to be similar as that of

123

I-IMT.

18

F-

18

F-FMT accumulates in the tumor

cells solely via amino acid transporter system L, especially the LAT1 subtype, and
shows no incorporation into proteins[76].
18

F-FMT can be successfully synthesized following a simple and quick

procedure designed by Tomiyoshi et al[77]. Briefly, [18F]F2 gas is converted to

18

F-

labelled acetylhypofluorite, which is then bubbled into the solution containing 10 mg
of L-α-methyltyrosine in 0.5 mL of trifluoroacetic acid (00C). The radiochemical yield
and purity of 18F-FMT were 20.3±5.1% and 99.4±0.3%, respectively.
In addition to its application in brain tumors,

18

F-FMT has also been

extensively investigated for its potential in detecting musculoskeletal tumor[78],
maxillofacial tumor[79], oral squamous cell carcinoma[80], and non-small cell lung
cancer[81-83]. In a study of 75 patients with musculoskeletal tumor, Watanabe et al
concluded that although

18

F-FDG may be better for tumor grading,

18

F-FMT had

higher specificity in differentiating between benign and malignant tumors[78]. In
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another study of patients with untreated malignant maxillofacial tumor,

18

F-FMT-

PET had better contrast of tumor visualization to the surrounding normal structures
than

18

F-FDG-PET in 27 out of 36 patients[79]. Furthermore, Kaira et al

demontrated that

18

F-FMT had no false-positives in detecting primary non-small cell

lung cancer and lymph node metastasis. In addition, they showed that LAT1
expression was a strong prognostic factor in non-small cell lung cancer patients,
and

18

F-FMT uptake in the tumor lesions was positively correlated with LAT1

expression (ρ=0.890)[81, 82].

3.

O-(2-18F-Fluoroethyl)-L-Tyrosine (18F-FET)
O-(2-18F-fluoroethyl)-L-Tyrosine (18F-FET) is a promising PET probe for

diagnosis of brain tumors and extracranial squamous cell carcinomas[84]. Several
strategies for

18

F-FET synthesis have been reported.

18

F-FET was initially prepared

via a 2-step procedure, alkylation of the L-tyrosine di-potassium salt with
[18F]fluoroethyltosylate (Fig. 1.3a)[85]. By following this procedure, 18F-FET could be
obtained in about 50 min with an overall yield of 40% and the specific activity
was >200 GBq/µmol. However, this procedure is not suitable for automation
because the separation and purification steps require HPLC. Later, the synthesis of
18

F-FET was improved by the implementation of direct nucleophilic radiofluorination

on protected alkyl tyrosine derivative, O-(2-tosyloxyethyl)-N-trityl-L-tyrosine tert.butylester (Fig. 1.3b). Although the radiochemical yield was much higher (60%), it
took about 80 min for the entire process to complete due to the neccessity of HPLC
purification to remove the solvent and an aggressive TFA[86]. So far, the best
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synthesis route of

18

F-FET, which suits perfectly for automation modules, was

reported by Krasikova et al in 2008[87]. It is a novel type of chiral enantiomercially
pure labeling precursor based on NiII complex of a Schiff’s base of (S)-[N-2-(N’benzylprolyl)amino]benzophenone (BPB) with alkylated (S)-tyrosine, Ni-(S)-BPB(S)-Tyr-OCH2CH2OTs (Fig. 1.3c). The overall synthesis time was 55 min, and the
radiochemical yield was 40-45%.
18

F-FET is primarily transported by the Na+-independent amino acid transport

system L, as well as the Na+-dependent amino acid transporter system B0,+ and B0.
18

F-FET is not incorporated into proteins[85].
For the clinical studies,

18

F-FET has always been compared to the same

amino acid-based radiotracer 11C-MET, or the gold standard of tumor imaging tracer
18

F-FDG. In a study of 16 patients with suspected primary or recurrent intracerebral

tumors,

18

F-FET-PET showed similar uptake and image contrast as those of

MET[88]. However,

11

C-

18

F-FET accumulates to a significantly greater extent in tumor

cells than in inflammatory cells when compared to

18

F-FDG or

11

C-MET, and

therefore, shows better differentiation between tumor and inflammatory lesions in
vivo[89, 90]. In fact, Popperl et al revealed that

18

F-FET-PET could reliably

distinguish post-therapeutic benign lesions, which may have a certain extent of
inflammation, from tumor recurrence after initial treatment of both low- and highgrade gliomas[91]. In addition, Plotkin et al concluded that
superior to

18

F-FET-PET was

18

F-FDG-PET for biopsy planning in patients with non-contrast-

enhancing brain tumors diagnosed by MRI[92]. Although

18

F-FET-PET itself already

has high sensitivity (88-100%), specificity (88-92.9%), and positive predictive value
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(84%) in glioma diagnosis[93-95], it is highly recommended to combine its
application with MRI and MR spectroscopy[94]. Furthermore, 18F-FET appears to be
suitable for the prognosis of glioma. Hutterer et al suggested that

18

F-FET-PET

might predict the failure of antiangiogenic treatment such as bevacizumabirinotecan in patients with recurrent high-grade glioma[96]. Besides, Floeth et al
suggested that the baseline amino acid uptake on

18

F-FET-PET and a diffuse

versus circumscribed tumor pattern on MRI were strong predictors for the outcomes
of treatments to patients with low-grade glioma[97]. When the dynamic

18

F-FET-

PET imaging in patients with glioblastoma is quantified, the ratio of standard uptake
value (SUV) to background may provide a more valuable predictive measurement of
the clinical outcome rather than the conventional SUV or distribution volume[98].
Unlike

18

F-FMT,

18

F-FET is more dedicated in brain tumor imaging. Several

studies were performed on the patients with head and neck cancer, however,

18

F-

FET imaging on those patients were not sensitive and specific enough to replace
the 18F-FDG[99-101].
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Fig. 1.3a. The initial synthetic scheme of O-2-[18F]fluoroethyl-L-tyrosine.
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IV.

Technetium-99m and its coordination with chelators
Technetium-99m ( 99mTc) -based radiopharmaceuticals have been developed

for cancer diagnostics since the 1960’s[102].

99m

Tc is an ideal radioisotope for

diagnostic imaging studies, because of its physical characteristics. It emits a 140
keV γ-ray in 89% abundance, which can be detected by NaI detectors with low
energy high-resolution collimator in the standard gamma camera[103].

99m

Tc has a

half-life of 6.02 h, which is ideal for preparation of radiolabeled small ligands and
proteins[14]. It can be produced with in-house generator that contains the parent
nuclide molybdenum-99 (99Mo), and does not require a cyclotron[104]. In addition,
technetium (Tc) is a second-row transition element in Group 7, right above rhenium
(Re), which has the radioisotope rhenium-188 (188Re) for cancer therapeutic
applications[103]. Therefore, Tc chemistry is very similar to that of Re, which forms
a diagnostic/therapeutic matched pair. Furthermore, due to their identical
coordination parameters with the same ligands, a Re complex is a good structural
model for the corresponding

99m

Tc complex because Re does not have any

radioactivity and the structure of its complex can be confirmed safely [103].
N,N’-ethylene-di-L-cysteine (EC) has been used as a strong chelator to trap
the radioisotopes such as

99m

Tc,

188

Re, and gallium-68 (68Ga)[105-107].

99m

Tc

labeled EC is used as a renal imaging agent, which shows identical imaging
properties but higher plasma clearance than the most widely used clinical agent,
99m

Tc-mercaptoacetyltriglycine (99mTc-MAG3)[107]. The rhenium complex of EC,

Re-EC, has also been synthesized and the structure has been determined by
single-crystal X-ray diffraction[107].
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On the other hand, 1,4,8,11-tetra-azacyclotetradecane (N4 cyclam), one of the
most common macrocyclic tetraamines, has also been reported as an efficient
chelator for

99m

Tc labeling[108, 109]. The

99m

Tc-N4 complex is hexacoordinate with

a trans-Tc (V)-dioxo core and positively charged (+1).
By taking the advantage of chelators such as EC and N4 cyclam, we can label
the tumor-target ligands with several different radioisotopes for SPECT or PET
imaging, and for the radiotherapeutic purposes, respectively.

V.

Scope of the dissertation
In this dissertation, four

99m

Tc-labeled tyrosine derivatives have been

synthesized and evaluated in vitro and in vivo for their imaging potentials in a breast
cancer model (Fig. 1.4). We chose tyrosine and its derivative α-methyl tyrosine
(AMT) as the target ligands based on the preexisting promising clinical outcomes of
application of their

18

F-labeled analogues. In addition, the structures of tyrosine and

AMT can be readily modified without changing their favorable biological
characteristics. In order to radiolabel tyrosine and AMT with

99m

Tc, we used

chelators EC and N4 cyclam, which have been reported to have the ability to stably
chelate with

99m

Tc[108, 110]. By taking advantage of the chelator technology, we

can label the same target ligand with different radioisotopes for various imaging
modalities in tumor diagnosis, or label the ligand with the therapeutic radioisotopes
for cancer treatment in future.
Our hypothesis is that

99m

Tc-labeled tyrosine/AMT-based radiotracers provide

great potential in breast cancer imaging by accumulating in tumor cells via the L-
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type amino acid transporter system (LAT), and they can well differentiate tumor
from inflammation. To test this hypothesis in each radiotracer, three specific aims
are addressed:
Specific Aim 1. Synthesize tyrosine/AMT-based precursor and label it with 99mTc.
Specific Aim 2. Investigate the uptake kinetics and transport mechanisms of 99mTclabeled tyrosine/AMT-based radiotracer in rat mammary tumor cell line 13762.
Specific Aim 3. Assess the kinetics of

99m

Tc-labeled tyrosine/AMT-based

radiotracer accumulation in tumor and inflammation tissues in a rat mammary tumor
model.
Chapter 1 has served as an introduction to the whole project. In Chapter 2-5,
each chapter describes the synthesis and biological evaluation of one compound.
Chapter 6 constitutes an overview of the project and compares four compounds
based on the three specific aims that were presumed to be addressed.
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CHAPTER 2

Development of

99m

Tc-EC-Tyrosine for breast cancer

imaging
I.

Introduction
Currently

18

F-FDG is the most common radiotracer for PET in tumor detection

and staging. However,

18

F-FDG has several limitations that give rise to false

positive/negative diagnosis. For instance,

18

F-FDG has poor contrast in brain tumor

due to the high glucose uptake in both normal and neoplastic brain tissues[111],
and it has poor differentiation of tumor from inflammatory tissue because of the high
18

F-FDG

uptake

in

granulocytes

and

macrophages[112,

113].

radiolabeled amino acids have been developed as an alternative to

Therefore,

18

F-FDG. Their

use in tumor detection is based on an increased uptake of amino acids in tumor
cells, which is assumed to reflect an enhanced amino acid transporter, metabolism,
and protein synthesis[114]. In contrast to glucose analog

18

F-FDG, the uptake of

amino acids in macrophages and other inflammatory cells is lower, so amino acidbased radiotracers are considered to be more specific than

18

F-FDG[84]. Among all

radiolabeled amino acids, aromatic ones such as tyrosine and its derivatives are
more suitable given their easier chemistry alterations and favorable biological
characterizations. To date, tyrosine and its α-methyl substituted analog AMT have
been successfully labeled with
imaging, as well as

11

C[115, 116],

18

F[75, 81] and

124/125

I[65] for PET

123/131

I[56] for SPECT imaging, respectively. Most of those

radiolabeled tyrosine analogs show promising preclinical and clinical results in
tumor imaging, particularly in brain tumor staging. In addition, they have been
proven to accumulate into the tumor cells predominantly via LAT, which is the only
31

system that can transport large neutral amino acids with aromatic rings[38, 41]. LAT,
especially its subtype LAT1, is an ideal target for tumor imaging because it is upregulated and highly expressed in many cancer cell lines and positively correlated
with tumor growth[117, 118].
Although the existing radiolabeled tyrosine and its derivatives have shown very
promising clinical outcomes, most of them require an on-site cyclotron to produce
the radioisotope, which is inconvenient and expensive. Besides, the half-life of the
radioisotopes are either too short (i.e. 20 min for

11

C) or too long (i.e. 57.4 days for

125

I). Furthermore, iodine-labeled compounds are not stable in vivo because of

deiodination. So far,

18

radiosynthesis yield of

F has the most appropriate half-life (110 min), however, the
18

F-labeled compounds appear to be relatively low because

of its electrophillic fluorination step. Therefore, it is desirable to develop a
radiotracer with simpler chemistry and affordable isotope, which can be used
clinically

in

most major medical facilities.

99m

Tc has favorable

physical

characteristics for diagnostic imaging studies. It emits a 140 keV gamma ray in 89%
abundance, which is commonly used by gamma camera and SPECT. Its relatively
long half-life (6.02 h) can provide serial images which overcomes the drawback of
Fluorine-18 [103]. The chelator EC is known to chelate

99m

Tc stably owing to the

efficient binding of the oxotechnetium group to two thiols and two amine nitrogen
atoms of EC[107]. By taking the advantage of using the chelator EC, we could label
several other radioisotopes such as Gallium-68, Indium-111, or Rhenium-188 with
the same ligand for diagnostic and therapeutic applications in future[105, 107]. Here,
we report the synthesis of

99m

Tc-labeled tyrosine using EC as a chelator, and its
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potential in breast tumor imaging is evaluated.

II.

Materials and methods

Chemicals and Analysis
EC was purchased from Taiwan Hopax Chems, Mfg, Co., Ltd. (Kaohsiung,
Taiwan). All other chemicals of analytical grades and solvents of HPLC grade were
obtained from Sigma-Aldrich (St. Louis, MO). Nuclear magnetic resonance (NMR)
was performed on Bruker 300MHz Spectrometer (Bruker BioSpin Corporation,
Billerica, MA), and mass spectra were performed on Waters Q-TOF Ultima Mass
Spectrometer (Milford, MA) at the chemistry core facility at the University of Texas
MD Anderson Cancer Center (UTMDACC; Houston, TX). Chemical shifts were
reported in δ (ppm) and J values in Hertz. Sodium pertechnetate (Na99mTcO4) was
obtained from 99Mo/99mTc generator by Mallinckrodt (Hazelwood, MO). 18F-FDG was
obtained from Department of Nuclear Medicine at UTMDACC.

Synthesis of Precursor EC-Tyrosine
a)

N-t-Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester (compound

1).
N-t-Butoxycarbonyl-L-tyrosine methyl ester (25 g; 0.085 mol) was dissolved in
acetone (300 mL). 1,3-dibromopropane (17.3 mL; 0.169 mol) and K2CO3 (58 g;
0.420 mol) were added under nitrogen. The reaction mixture was refluxed at 80 oC
overnight. After cooling and filtration, the solvent was removed under reduced
pressure, and the residue was dissolved in chloroform. The residue was washed
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with water and dried with anhydrous MgSO4. The product was purified by column
chromatography using a silica gel column, eluted with hexane/ethyl acetate (2:1 v/v)
to yield 33.3 g (94.6%). Ms(m/z): 440.09 [M+Na]+.

b)

N-t-Butoxycarbonyl-O-[3-(N-Ethylenedicysteine) propyl]-L- tyrosine

(compound 2).
EC (4.7 g, 17.6 mmol) was dissolved in water (50 mL), and the pH was
adjusted to pH 8-9 by NaOH (1N). Compound 1 (5.1 g, 12.3 mmol) in ethanol (100
mL) was added to the above solution, followed by adding K2CO3 (12.13 g, 88 mmol).
Reaction mixture was then heated at 80 oC overnight. After cooling, the solvent was
removed under reduced pressure, and the residue was dissolved in chloroform (50
mL). The residue was washed with water, dried with anhydrous MgSO4, and
evaporated to dryness. Without further purification, the compound 2 was used for
following steps.

c)

O-[3-(N-Ethylenedicysteine) propyl]-L- tyrosine (EC-Tyrosine)

(compound 3).
The crude product of compound 2 (2.5 g, 4.24 mmol) was dissolved in ethanol
(50 mL). Hydrobromic acid (48%, 4.5 mL) was added dropwisely to the solution over
30-min period at room temperature with stirring. After filtration, the white solid was
washed with ethanol and recrystallized in water to yield 1.73 g.

Radiolabeling of EC-Tyrosine and EC with 99mTc
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EC-Tyrosine (1 mg) was dissolved in 0.2 mL sterile water, followed by adding
tin (II) chloride (0.1 mL, 1 mg/mL). For EC labeling, EC (0.5 mg) was dissolved in
0.2mL sterile water by adding 10 uL of 1N NaOH (pH=9). Required amount of
Na99mTcO4 was added to EC or EC-Tyrosine solution (pH 7.4). Radiochemical purity
was determined by radio-HPLC (High performance liquid chromatography; Waters,
Milford, MA), eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min.

Determination of the Partition Coefficient
To determine the lipophilicity, 20 µL of

99m

Tc-EC-Tyrosine was added into an

equal volume mixture of 1-octanol and sterile water in a centrifuge tube. The
mixture was vortexed at room temperature for 1 min and then centrifuged at 5000
rpm for 5 min. From each phase, 0.1 mL of the aliquot was taken out and the
radioactivity was measured by gamma counter (Cobra Quantum; Packard, MN).
The measurement was repeated for three times, and care was taken to avoid cross
contamination between the phases. The partition coefficient value, expressed as
logP, was calculated using the following equation:
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer)

In Vitro Cellular Uptake Studies
Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville,
MD) was selected and the same cell line was used to create the animal model for in
vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium and
nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in a
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humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue
culture plates (2x105 cells/well) and incubated with

99m

Tc-EC-Tyrosine (0.05 mg/well,

8 uCi/well), the negative control 99mTc-EC (0.025 mg/well, 8 uCi/well), or 18F-FDG (8
uCi/well) for 0-4 h. After incubation, cells were washed with ice-cold PBS twice and
detached by treating them with 0.5 mL of trypsin for 5 min. Cells were then collected
and the radioactivity was measured with gamma counter. Data were expressed in
mean ±S.D. percent of cellular uptake (%Uptake) in triplicate.

In Vitro Competitive Inhibition Study
To investigate the transport mechanisms of 99mTc-EC-Tyrosine, the competitive
inhibition study using L-tyrosine was conducted. Rat breast tumor cells were coincubated with 99mTc-EC-Tyrosine (8 µg/well, 8 µCi/well) and L-tyrosine for up to 1 h.
A set of concentrations of L-tyrosine (10x, 50x, and 100x of the EC-Tyrosine
concentration) were used. After incubation, cells were washed with ice-cold PBS
twice and detached by treating them with 0.5 mL of trypsin for 5 min. Cells were
then collected and the radioactivity was measured by gamma counter. Data were
expressed in mean ±S.D. percent of cellular uptake (%Uptake) in triplicate.

Blood Clearance
All animal work was carried out in the Small Animal Imaging Facility (SAIF) at
UTMDACC under a protocol approved by Institutional Animal Care and Use
Committee (IACUC). For blood clearance analysis, three normal female Fischer 344
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously
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injected with 30 µCi

99m

Tc-EC-Tyrosine. Blood samples were drawn through lateral

tail vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10
µL). The blood samples were measured for radioactivity by gamma counter, and
then were calculated as percentage of the injected dose per gram of blood (%ID/g).

In Vivo Tissue Distribution Study of 99mTc-EC-Tyrosine
Tissue distribution studies of

99m

Tc-EC-Tyrosine (study I, n=9) and

18

F-FDG

(study II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g,
n=18). For each compound, the rats were divided into three groups for three time
intervals (0.5, 2, 4 h for

99m

Tc-EC-Tyrosine; 0.5, 1, 2 h for

18

F-FDG; n=3/time point).

The injection activity was 25±0.5 µCi/rat intravenously. At each time interval, the
rats were sacrificed, and the selected tissues were excised, weighed and measured
for radioactivity by gamma counter. Each sample was calculated as percentage of
the injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted
sample of the original injection were used as reference.

Planar Scintigraphic Imaging Study
Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast
5

tumor cells 13762 suspension in PBS (10 cells/rat) into the right legs. Planar
scintigraphic imaging of

99m

Tc-EC-Tyrosine was performed 12-14 days after

inoculation when tumors reached approximately 1 cm in diameter. Planar
scintigraphic images were obtained using M-CAM (Siemens Medical Solutions,
Hoffman Estates, IL) equipped with a Low Energy High Resolution collimator.
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Anesthetized breast tumor-bearing rats were injected intravenously with

99m

Tc-EC-

Tyrosine (0.3 mg/rat, 300 µCi/rat; n=3). The images were acquired up to 4 h postadministration of tracers. Computer outlined regions of interest (ROIs in counts per
pixel) between tumor and muscle were used to calculate tumor/muscle (T/M) ratios.
Percentage of the injected dose (%ID) of tumor was also calculated from the
reference standard, which was 1/10 of the original injection activity.

In Vivo Uptake Blocking Study
To ascertain whether

99m

Tc-EC-Tyrosine uptake is mediated specifically by

LAT, in vivo blocking studies using the unlabeled L-Tyrosine as the competitive
inhibitor was conducted. The same animal model used in the planar scintigraphic
imaging study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL
saline (pH adjusted to 2-3) was administered intravenously to mammary tumor–
bearing rats 1 h prior to

99m

Tc-EC-Tyrosine injection. Planar scintigraphic images

were acquired up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to
calculate the ratios of liver/muscle, kidney/muscle, and tumor/muscle, respectively.
In addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the
reference standard, which was 1/10 of the original injection activity. The results
were compared with those from the rats injected with
(control).

Tumor and Inflammation Uptake Comparison In Vivo
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99m

Tc-EC-Tyrosine alone

To investigate whether

99m

Tc-EC-Tyrosine can differentiate tumor from the

inflammatory tissue, a rat model bearing both mammary tumor and turpentine oilinduced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was
injected into the left calf muscles of the rats to induce inflammation. The
anesthetized rats (n=3) were injected intravenously with

99m

Tc-EC-Tyrosine 24 h

after the turpentine injection. Planar scintigraphic images were acquired up to 4 h,
and ROIs of tumor, inflammation, and muscle were used to calculate the tumor-tomuscle

ratios

(T/Ms),

inflammation-to-muscle

ratios

(I/Ms),

and

tumor-to-

inflammation ratios (T/Is), respectively. Same animal model was used to evaluate
18

F-FDG. Micro-PET imaging of

18

F-FDG was performed using R4 micro-PET

scanner (Concorde Microsystems, TN). The rats were injected intravenously with
18

F-FDG (500 uCi/rat, n=3), and dynamic PET scans were obtained for 90 min with

a spatial resolution of 2.2 mm. PET images were reconstructed by using the
ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3)
that were estimated from the average pixels within ROIs drawn around the tumor,
inflammation or muscle on transverse slices of the reconstructed image sets.

III.

Results

Chemistry and radiochemistry
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The synthetic scheme of precursor EC-Tyrosine is shown in Fig. 2.1. The
structure and purity of EC-Tyrosine were confirmed by 1H- and

13

C- NMR, mass

spectra, and HPLC, respectively. The total synthesis yield of EC-Tyrosine was 79.5%
(3-step). The 1H- and

13

C-NMR results were 1H-NMR (D2O, δ/ppm): 7.01 (d, 2H,

phenyl ring), 6.79 (d, 2H, phenyl ring), 3.94 (dd, 2H, O-CH2), 3.27(t, 2H, CHN), 2.87
(d, 2H, PhCH2-), 2.68-2.40(m, 8H, -CH2-), 1.88(m, 2H, C-CH2-C).

13

C-NMR (D2O,

δ/ppm): 182.22, 182.22, 180.16, 156.69, 130.85, 130.50, 130.50, 114.85, 114.85,
66.89, 62.66, 57.35, 57.35, 46.28, 39.61, 34.29, 28.31, 28.20.
99m

Precursor EC-Tyrosine could be labeled with

Tc with high radiochemical
99m

purities (> 95%). The partition coefficient value (logP) of

Tc-EC-Tyrosine was -

2.02±0.168.
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Figure 2.1. Synthetic scheme of precursor EC-Tyrosine.
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N

HS

In Vitro Cellular Uptake Studies
The cellular uptake kinetics of

99m

Tc-EC-Tyrosine,

99m

Tc-EC, and

using 13762 rat breast tumor cells is shown in Fig. 2.2. The uptake of

18

F-FDG

99m

Tc-EC-

Tyrosine into the tumor cells increased rapidly, and reached 1.02%Uptake at 4 h. In
addition, the %Uptake of

99m

Tc-EC-Tyrosine was much higher than that of

18

F-FDG

and the negative control 99mTc-EC.
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Figure 2.2. Time course of 99mTc-EC-Tyrosine, 99mTc-EC and 18F-FDG uptake in rat
breast tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D.
percentage of cellular uptake (%Uptake).
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Competitive Inhibition Study of 99mTc-EC-Tyrosine
After incubated with L-tyrosine at 10-100 times as high as the concentrations
of EC-Tyrosine,

99m

Tc-EC-Tyrosine showed a significantly decreased uptake,

especially for 50 and 100 times concentration groups (Fig. 2.3). These results
suggest that

99m

Tc-EC-Tyrosine is transported at least partially via the same

transporter system LAT as L-tyrosine is.
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Figure 2.3. Competitive inhibition uptake of 99mTc-EC-Tyrosine by L-tyrosine in rat
breast tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [10X–
100X of EC-Tyrosine concentration (8 mg/well)] were used. Data are expressed in
mean ± S.D. percentage of cellular uptake (%Uptake).
*P<0.05 compared with the control group.
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Blood clearance
The blood clearance curve for

99m

Tc-EC-Tyrosine in normal Fischer 344 rats

(n=3) is shown in Fig. 2.4. The plasma half-life of the distribution phase (t1/2 α) was
13.68±1.067 min, and that of the elimination phase (t1/2 β) was 117.51±5.727 min.
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Figure 2.4. Blood clearance (%ID/g) of 99mTc-EC-Tyrosine in normal female Fischer
344 rats (n=3). The data represent the mean radioactivity expressed as a percentage
of the injected dose per gram of blood ± S.D.
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In Vivo Tissue Distribution Study of 99mTc-EC-Tyrosine
The tissue distribution results of 99mTc-EC-Tyrosine and

18

F-FDG in the normal

Fischer 344 rats are shown in Tables 2.1 and 2.2, respectively. Low thyroid and
stomach uptake of

99m

Tc-EC-Tyrosine was observed, suggesting its high stability in

vivo. In addition, kidneys had high uptake of 99mTc-EC-Tyrosine at all time-points.

Table 2.1. Biodistribution of 99mTc-EC-Tyrosine in normal Fischer 344 female rats.

30 MIN

%ID/g

120 MIN

240 MIN

blood

0.96 ±0.076

0.41 ±0.039

0.23 ±0.006

heart

0.24 ±0.007

0.12 ±0.011

0.08 ±0.009

lung

0.47 ±0.041

0.33 ±0.001

0.20 ±0.025

thyroid

0.43 ±0.036

0.24 ±0.001

0.11 ±0.002

pancreas

0.21 ±0.018

0.17 ±0.016

0.10 ±0.007

liver

1.47 ±0.045

2.42 ±0.075

0.97 ±0.007

spleen

0.47 ±0.054

1.41 ±0.117

0.62 ±0.036

kidney

11.12 ±0.545

16.50 ±0.395

11.13 ±0.234

stomach

0.27 ±0.006

0.19 ±0.002

0.08 ±0.000

intestine

1.13 ±0.009

0.33 ±0.023

0.17 ±0.017

muscle

0.10 ±0.009

0.05 ±0.006

0.03 ±0.000

bone&joint

0.28 ±0.021

0.10 ±0.003

0.07 ±0.009

brain

0.04 ±0.003

0.01 ±0.001

0.01 ±0.001

Each rat received

99m

Tc-EC-Tyrosine (25 µCi, intravenously). Each value is percent of

injected dose per gram weight (n= 3)/time interval. Each data represents mean of three
measurements with standard deviation.
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Table 2.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats.

%ID/g

30 MIN

60 MIN

blood

0.40 ±0.042

0.13 ±0.006

0.06 ±0.002

heart

1.57 ±0.056

1.38 ±0.126

1.08 ±0.068

lung

0.55 ±0.056

0.42 ±0.024

0.46 ±0.027

thyroid

1.07 ±0.080

1.04 ±0.040

1.05 ±0.069

pancreas

0.26 ±0.028

0.21 ±0.006

0.20 ±0.016

liver

0.40 ±0.048

0.16 ±0.006

0.13 ±0.012

spleen

0.82 ±0.081

0.74 ±0.032

0.86 ±0.071

kidney

0.71 ±0.051

0.37 ±0.012

0.24 ±0.018

stomach

0.61 ±0.078

0.44 ±0.031

0.39 ±0.030

intestine

0.69 ±0.068

0.53 ±0.035

0.52 ±0.025

muscle

0.33 ±0.040

0.34 ±0.027

0.74 ±0.024

bone& joint

0.33 ±0.036

0.44 ±0.065

0.50 ±0.034

brain

2.00 ±0.149

1.99 ±0.046

1.39 ±0.086

Each rat received

120 MIN

18

F-FDG (25 µCi, intravenously). Each value is percent of injected dose

per gram weight (n =3)/time interval. Each data represents mean of three measurements
with standard deviation.
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Planar Scintigraphic Imaging Study
The selected planar scintigraphic images of

99m

Tc-EC-Tyrosine at 30 min, 2h,

and 4 h in breast tumor-bearing rats are shown in Fig. 2.5. Tumors were clearly
detected by

99m

Tc-EC-Tyrosine at all time-points. The T/M ratios at 30 min, 2h, and

4 h were 4.54, 5.25, and 4.92, respectively. Tumor %IDs at these three time-points
were 2.16%, 1.62%, and 1.57%, respectively (Fig. 2.5).

30 MIN

120 MIN

240 MIN

T

T/M = 4.54
Tumor %ID: 2.16

T/M = 5.25
Tumor %ID: 1.62

T/M = 4.92
Tumor %ID: 1.57

Figure 2.5. Planar scintigraphy of 99mTc-EC-Tyrosine at 30 – 240 min in rat breast
tumor-bearing rats (T: tumor).
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In Vivo Uptake Blocking Study
The liver, kidneys, tumor, and muscle %IDs, as well as the ratios of these
organs to muscle before and after in vivo blocking by unlabeled L-Tyrosine were
listed in Table 2.3 and 2.4. The organ-to-muscle ratios of

99m

Tc-EC-Tyrosine after

using the blocking agent L-tyrosine decreased at all time intervals compared to the
control group. However, this observation was not because of the decreased uptake
of liver, kidneys or tumor, but due to the increased
muscle (Table 2.3).

99m

99m

Tc-EC-Tyrosine uptake by

Tc-EC-Tyrosine uptake at tumor site could only be blocked

at 30 min, suggesting that

99m

Tc-EC-Tyrosine and unlabeled L-Tyrosine might be

uptaken via the same amino acid transporter LAT very rapidly.

Table 2.3. Percentage of injected dose (%ID) of selected organs before and after in vivo
blocking of

99m

Tc-EC-Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats.

Red font indicates the decreased %ID when compared to the corresponding control
group. Blue shading indicates P<0.05 when compared to the corresponding control
group (n=3/group/time interval).
30 min

2 hr

4hr

%ID
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver

6.23±0.34

6.67±0.42

-7.06%

6.06±0.27

5.11±0.12

15.68%

5.90±0.54

5.62±0.51

4.75%

Kidney

11.36±0.53

9.87±0.61

13.12%

9.73±0.31

8.36±0.29

14.08%

7.46±0.21

10.62±0.17

-42.36%

Tumor

1.36±0.08

1.28±0.15

5.88%

0.82±0.06

0.95±0.09

-15.85%

0.69±0.11

0.83±0.05

-20.29%

Muscle

0.32±0.03

0.58±0.05

-81.25%

0.24±0.06

0.36±0.05

-50.00%

0.15±0.02

0.23±0.04

-53.33%
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Table 2.4. Selected organ to muscle ratios before and after in vivo blocking of

99m

Tc-EC-

Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the
decreased %ID when compared to the corresponding control group. Blue shading
indicates P<0.05 when compared to the corresponding control group (n=3/group/time
interval).
30 min

2 hr

4hr

Ratio
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver/Muscle

19.7±1.1

11.5±0.6

41.62%

61.7±1.7

14.2±0.4

76.99%

39.7±2.4

24.7±1.6

37.78%

Kidney/Muscle

36.0±1.4

17.0±1.2

52.78%

99.1±3.2

23.3±2.4

76.49%

50.2±3.4

46.6±3.1

7.17%

Tumor/Muscle

4.25±0.12

2.21±0.23

48.00%

3.42±0.25

2.64±0.29

22.81%

4.64±0.06

3.64±0.35

21.55%
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Tumor and Inflammation Uptake Comparison In Vivo
99m

The representative planar scintigraphic images of
well as the micro-PET images of

Tc-EC-Tyrosine, as

18

F-FDG in breast tumor and inflammation-bearing

rats are shown in Fig. 2.6 and Fig. 2.7, respectively. The T/M of

99m

Tc-EC-Tyrosine

at each time interval was much higher than I/M. In addition, the T/I of
Tyrosine at the last time-point was even higher than that of
which

suggested

that

99m

Tc-EC-Tyrosine

could

99m

Tc-EC-

18

F-FDG (2.47 vs. 1.80),

differentiate

tumor

from

inflammation very well.

30 MIN

120 MIN

240 MIN

I
T

T/M
I/M
T/I

30 min

2 hr

4 hr

4.30

8.36

4.64

3.02

4.31

1.88

1.43

1.94

2.47

Figure 2.6. Planar scintigraphic images of 99mTc-EC-Tyrosine at 30 – 240 min in rat
breast tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-tomuscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-toinflammation ratios (T/Is) are listed below the figure.
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Transverse

T

Saggital

Axial

I
T

T

I

I

30 min

60 min

90 min

T/M
I/M
T/I

30 min

60 min

90 min

5.88

7.54

4.90

3.43

3.77

2.72

1.71

1.99

1.80

Figure 2.7. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is)
are listed below the figure.
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IV.

Discussion
In the present study, we report the synthesis of

99m

Tc-labeled tyrosine using

EC as a chelator, and its potentials in breast cancer diagnosis by using the breast
tumor models in vitro and in vivo are evaluated.
For chemical synthesis, the precursor EC-Tyrosine was successfully
synthesized with an overall yield of 79.5%. Since the starting material N-tButoxycarbonyl-L-tyrosine methyl ester was commercially available, it took only
three steps to obtain the final product EC-Tyrosine. The mild aqueous solution
instead of the traditional organic solution was used for the coupling reaction of EC
with N-t-Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester (compound 1),
which is a very efficient method. In this reaction, the molar ratio of EC and N-tButoxycarbonyl-O-[3-Br-propyl]-L-tyrosine

methyl

ester

(compound

1)

was

controlled accurately in 2:1 in order to avoid each EC conjugating with more than
one Tyrosine. The structure of EC-Tyrosine was well confirmed with the NMR and
mass spectra results; therefore, tyrosine was assured to be conjugated with EC
specifically on the nitrogen atom, but not on the sulfur atom.
When the precursor EC-Tyrosine was labeled with
purity was more than 95%. Since

99m

99m

Tc, the radiochemical

Tc-EC-Tyrosine is a kit-product and labeled

without any further purification, the radiochemical yield was assumed to be identical
to its radiochemical purity. The partition coefficient value (logP) of
Tyrosine was slightly lower than its α-methyl derivative

99m

99m

Tc-EC-

Tc-EC-AMT (-2.02±0.168

vs.-1.14±0.072, reported in Chapter 3), which supports our hypothesis. It is wellknown that the lower logP indicates the lower lipophilicity of the compound. In our
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hypothesis, we speculated that the lipophilicity of tyrosine-based radiotracer could
be increased by adding a methyl group on its α-carbon.
In cellular uptake study,

99m

Tc-EC-Tyrosine was taken up rapidly by rat

mammary tumor cells, and the %Uptake of

Tc-EC, suggesting high specificity of

Tc-EC-Tyrosine in tumor uptake. Besides,

uptake than
study,

99m

Tc-EC-Tyrosine was significantly

99m

higher than that of the negative control
99m

99m

99m

Tc-EC-Tyrosine even has higher

18

F-FDG in this in vitro breast cancer model. In competitive inhibition

Tc-EC-Tyrosine uptake was significantly inhibited by L-tyrosine at 50x and
99m

100x concentrations, which suggests that

Tc-EC-Tyrosine is transported at least

partially via the same transporter system LAT that L-tyrosine exploits. These
findings were consistent with those of many other radiolabeled tyrosine analogs. For
instance,

11

C/14C-tyrosine[119],

123 125

I/

I-labeled

AMT[56,

120],

18

F-labeled

tyrosine[121], AMT[76], and fluoroethyltyrosine (18F-FET) [114] have been proven to
be predominantly transported via amino acid transporter LAT. Since the increased
expression level of LAT has been observed in various types of tumors[38],
upregulated LAT is a suitable target for tumor imaging.
For in vivo evaluation, 99mTc-EC-Tyrosine had a relatively fast blood clearance
in normal Fischer 344 rats (Fig. 2.4). Biodistribution study showed that

99m

Tc-EC-

Tyrosine had high uptake in kidneys of normal rats (Table 2.1), which was
consistent with the imaging findings in the breast tumor-bearing rats (Fig. 2.5).This
may partially due to the characteristics of EC given that

99m

Tc-EC itself is known as

a renal tubular imaging agent[122]. In addition, the similar results were observed in
99m

Tc-labeled EC-chelated AMT analogue
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99m

Tc-EC-AMT (reported in Chapter 3).

Compared to

99m

Tc-EC-AMT,

99m

Tc-EC-Tyrosine had even higher kidney uptake,

which may be owing to its lower lipophilicity. The compound with lower lipophilicity
is more water soluble, therefore, is more likely to be metabolized and excreted by
kidneys. Furthermore, Shikano et al. confirmed that the uptake of

123

I-labeled AMT

(123I-AMT) into normal human renal proximal tubule epithelial cells could be
significantly inhibited by BCH, an LAT specific inhibitor[123]. This result suggests
that LAT is involved in radiolabled tyrosine uptake in kidneys. To ascertain whether
99m

Tc-EC-Tyrosine uptake is mediated specifically by LAT, the in vivo uptake

blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor were
conducted (Table 2.3 and 2.4). Although the organ-to-muscle ratios of

99m

Tc-EC-

Tyrosine after using the blocking agent L-tyrosine decreased at all time intervals
compared to the control group, this observation was caused by the increased 99mTcEC-Tyrosine uptake in muscle (Table 2.3).

99m

Tc-EC-Tyrosine uptake at tumor site

could only be blocked at 30 min, suggesting that

99m

Tc-EC-Tyrosine and unlabeled

L-Tyrosine might be uptaken via the same amino acid transporter LAT very rapidly.
These in vivo findings were coherent with the in vitro competitive inhibition results.
The most important finding in our study was the high suitability of
Tyrosine to differentiate tumor from inflammation. The T/M of

99m

each time-point was much higher than I/M. In addition, the T/I of
at the last time-point was even higher than that of
one of the biggest limitations of

99m

Tc-EC-

Tc-EC-Tyrosine at

99m

Tc-EC-Tyrosine

18

F-FDG (2.47 vs. 1.80). Since

18

F-FDG in clinic is that it cannot distinguish tumor

from inflammatory site very well,

99m

Tc-EC-Tyrosine may promise an ideal

alternative to 18F-FDG in future.
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In summary, EC-Tyrosine was synthesized and labeled with

99m

Tc readily and

efficiently with high radiochemical purity. In vitro cellular uptake study demonstrated
that

99m

Tc-EC-Tyrosine transport involved amino acid transporter system LAT. Due

to its simple chemical synthesis procedure, high cost effectiveness of the isotope,
and comparatively high tumor/muscle uptake ratios in planar imaging,

99m

Tc-EC-

Tyrosine has great potential for breast cancer imaging, especially in differential
diagnosis of tumor from inflammation. By taking the advantages of the coordination
capability of chelator, EC-Tyrosine could chelate various radioisotopes for either
imaging or therapy in the future.
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CHAPTER 3

99m

Development of

Tc-EC-AMT for breast cancer

imaging (partially adapted from [124])
I.

Introduction
18

F-FDG-PET is a gold standard for tumor detection and staging in clinic.

Unfortunately,

18

F-FDG

has

several

limitations

that

give

rise

to

false

positive/negative diagnosis and poor predictive value of tumor response to
chemo/radio therapy[125]. 18F-FDG has poor contrast in brain tumor due to the high
uptake of glucose in both normal and neoplastic brain tissues[111], and it has poor
differentiation of tumor from inflammatory tissue, because of the high uptake of

18

F-

FDG in granulocytes and macrophages[112, 113]. Radiolabeled amino acids show
relatively low accumulation in normal tissues, rather high accumulation in tumor
tissue, and rapid blood clearance[32]. These radiolabeled amino acids are attractive,
since the main determinant of their uptake is amino acid transporters that are
generally upregulated in cancer cells[76, 126]. Upregulated amino acid transporters
indirectly reflect elevated cell proliferation[127], and assessment of their activities
promises potential applications in differential diagnosis and prediction of early
treatment response. Among all radiolabeled amino acids, aromatic amino acids are
more suitable for tumor imaging due to easier chemical modification and
characterization. However, aromatic amino acids tend to be decarboxylated[128],
which reduces its ability to enter cells via amino acid transporters. Placing a methyl
group at the alpha position could slower its metabolic process, thus, extensive
amount of effort was directed towards the

18

F- and

123/124

I-labeled α-carbon-

methylated aromatic amino acids such as 2-[18F]fluoromethyl-L-phenylalanine[129],
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2- and 3-L-[18F]fluoro-α-methyl tyrosine (18F-FAMT)[75, 81, 130], and

123

I-labeled L-

3-[123I]iodo-α-methyltyrosine (123I-AMT)[56].
18

Clinical study in lung cancer patients showed that

F-FAMT had no false-

positives in detecting primary tumors and lymph node metastases, and was able to
improve the diagnostic performance in non-small cell lung cancer[81].

18

F-FAMT

has been proven to be transported into the tumor cells solely via the LAT system,
especially the LAT1 subtype[76]. LAT is the only system that can transport large
neutral amino acids with aromatic rings such as tyrosine, phenylalanine, and
tryptophan[38, 41]. LAT family is known to form heterodimers, which contain a
chaperone-like heavy chain 4F2hc, and a 12-time transmembrane light chain that is
unique to each subtype[117]. Previous clinical studies showed that uptake of

18

F-

FAMT in tumors was positively correlated with LAT1 expression and cell
proliferation[81]. Although application of

18

F-FAMT-PET shows very promising

clinical results, its radiosynthesis yield is relatively low, and the cost of using PET
isotope

18

F is prohibitive. Therefore, it is desirable to develop a radiotracer with

simpler chemistry and affordable isotope, which can be used clinically in most major
medical facilities.
99m

Tc is an ideal radioisotope for diagnostic imaging studies, due to its physical

characteristics. It emits a 140 keV gamma ray in 89% abundance [103], which is
commonly used by SPECT. The half-life of

99m

Tc is 6.02 h, which can provide serial

images and therefore overcome the drawback of

18

F. Diaminodithiol (N2S2)

compounds are known to form considerably stable Tc (V) O-complexes owing to the
efficient binding of the oxotechnetium group to two thiols and two amine nitrogen
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atoms[107]. EC is the most successful example of N2S2 chelates[106, 131].
Previously, we reported that EC-conjugates can be labeled with

99m

Tc via a peptide

bond efficiently with high radiochemical purity, and the complex remains stable[131].
Here, we report the synthesis of

99m

Tc-labeled AMT using EC as a chelator and

evaluation of its potential use in breast tumor imaging.

II.

Materials and methods

Chemicals and Analysis
All chemicals and sources used here were previously described in Chapter 2.

Synthesis of Precursor EC-AMT
a) α-Methyl tyrosine ethylester (compound 1).
Thionyl chloride (18 mL; 0.24 mol) was added to α-methyltyrosine (15.0 g; 0.08
mol) in anhydrous ethanol (100 mL) at 0 oC. The mixture was refluxed at 80-90 oC
overnight with stirring. After cooling, the solvent was evaporated in vacuo to dryness.
A saturated solution of NaHCO3 (150 mL) was added to the residue. White solid
was filtered and washed with water and recrystallized in ethanol and water to yield
15.7 g (91.7%). MS(m/z): 224.23 [M]+.

b) N-t-Butoxycarbonyl-α-methyltyrosineethylester (compound 2).
Compound

1

(15.48

g;

69.35

mmol)

was

dissolved

in

anhydrous

dichloromethane (200 mL). Di-tert-butyl dicarbonate (15.14 g; 69.35 mmol) and
NaHCO3 (58.3 g, 0.69 mol) were added. Reaction mixture was stirred overnight at
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50 oC, and the white solid was removed by filtration. The solution was washed with
water and dried over anhydrous MgSO4. The product was purified by column
chromatography using a silica gel column, and eluted with hexane/ethyl acetate (5:2
v/v) to yield 8.97 g (40%). MS(m/z): 346.16 [M+Na]+.

c) N-t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine ethylester
(compound 3).
Compound 2 (9.42 g; 0.029 mol) was dissolved in acetone (200 mL). 1,3dibromopropane (11.0 mL; 0.115 mol) and K2CO3 (10.0 g; 0.178 mol) were added
under nitrogen. The reaction mixture was refluxed at 70-80 oC overnight. After
cooling and filtration, the solvent was removed under reduced pressure, and the
residue was dissolved in chloroform. The residue was washed with water and dried
with anhydrous MgSO4. The product was purified by column chromatography using
a silica gel column, eluted with hexane/ethyl acetate (4:1 v/v) to yield 11.0 g (86%).
Ms(m/z): 445.10 [M]+.

d) N-t-Butoxycarbonyl-O-[3-(N-Ethylenedicysteine) propyl]-α-methyl tyrosine
(compound 4).
EC (3.33 g, 12.4 mmol) was dissolved in water (50 mL), and the pH was
adjusted to pH 9-10 by NaOH (1N). Compound 3 (3.86 g, 8.69 mmol) in ethanol (80
mL) was added to the above solution, followed by adding K2CO3 (8.6 g, 62.2 mmol).
Reaction mixture was then heated at 90 oC overnight. After cooling, the solvent was
removed under reduced pressure, and the residue was dissolved in chloroform (50
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mL). The residue was washed with water, dried with anhydrous MgSO4, and
evaporated to dryness. Without further purification, the compound 4 was used for
following steps.

e) O-[3-(N-Ethylenedicysteine) propyl]-α-methyl tyrosine (EC-AMT) (compound
5).
The crude product of compound 4 (2.5 g, 0.04 mol) was dissolved in
dichloromethane (50 mL). Hydrobromic acid (48%, 4.5 mL) was added dropwisely
to the solution over 30 min periods at room temperature with stirring. After filtration,
the white solid was washed with ethanol and recrystallized in water to yield 2.08g
(86%).

f) Rhenium- O-[3-(N-Ethylenedicysteine) propyl]-α-methyl tyrosine (Re-ECAMT) (compound 6).
An ethanol solution (10 mL) containing trichlorooxobis (triphenylphosphine)
rhenium (V) (110 mg, 0.13 mmol) was added to an aqueous solution (10 mL) with
EC-AMT (66 mg, 0.13 mmol) and potassium hydroxide (120 mg, 1.3 mmol),
followed by refluxing at 90 °C for 1 h. The color of reaction mixture changed from
green to yellow. After cooling and filtration, the ethanol was removed in vacuo. The
remaining aqueous solution was acidified to pH 4 with 1N HCl. The yellow solid
product (Re-EC-AMT) formed immediately was collected and recrystallized from
water. Ms (m/z): 739.29 [M+HCl] +.
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Radiolabeling of EC-AMT and EC with 99mTc
EC-AMT (1 mg) was dissolved in 0.2 mL sterile water, followed by adding tin (II)
chloride (0.1 mL, 1 mg/mL). For EC labeling, EC (0.5 mg) was dissolved in 0.2mL
sterile water by adding 10 uL of 1N NaOH (pH=9). Required amount of Na99mTcO4
was added to EC or EC-AMT solution (pH 7.4). Radiochemical purity was
determined by radio-HPLC (High performance liquid chromatography; Waters,
Milford, MA), eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min.

Determination of the Partition Coefficient
To determine the lipophilicity, 20 µL of

99m

Tc-EC-AMT was added into an equal

volume mixture of 1-octanol and sterile water in a centrifuge tube. The mixture was
vortexed at room temperature for 1 min and then centrifuged at 5000 rpm for 5 min.
From each phase, 0.1 mL of the aliquot was taken out and the radioactivity was
measured by gamma counter (Cobra Quantum; Packard, MN). The measurement
was repeated for three times, and care was taken to avoid cross contamination
between the phases. The partition coefficient value, expressed as logP, was
calculated using the following equation:
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer)

In Vitro Cellular Uptake Studies
Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville,
MD) was selected and the same cell line was used to create the animal model for in
vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium and
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nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in a
humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue
culture plates (2x105 cells/well) and incubated with
uCi/well),

99m

Tc-EC (0.025 mg/well, 8 uCi/well) or

99m

Tc-EC-AMT (0.05 mg/well, 8

18

F-FDG (8 uCi/well) for 0-4 h.

After incubation, cells were washed with ice-cold PBS twice and detached by
treating them with 0.5 mL of trypsin for 5 min. Cells were then collected and the
radioactivity was measured with gamma counter (Cobra Quantum; Packard, MN).
Data were expressed in mean ±S.D. percent of cellular uptake (%Uptake) in
triplicate.

Competitive Inhibition Study of 99mTc-EC-AMT
To investigate the transport mechanisms of

99m

Tc-EC-AMT, the competitive

inhibition study using L-tyrosine was conducted. Rat breast tumor cells were coincubated with

99m

Tc-EC-AMT (8 µg/well, 8 µCi/well) and L-tyrosine for up to 1 h. A

set of concentrations of L-tyrosine (10x, 50x, and 100x of the EC-AMT
concentration) were used. After incubation, cells were washed with ice-cold PBS
twice and detached by treating them with 0.5 mL of trypsin for 5 min. Cells were
then collected and the radioactivity was measured by gamma counter. Data were
expressed in mean ±S.D. percent of cellular uptake (%Uptake) in triplicate.

Blood Clearance
All animal work was carried out in the Small Animal Imaging Facility (SAIF) at
UTMDACC under a protocol approved by Institutional Animal Care and Use
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Committee (IACUC). For blood clearance analysis, three normal female Fischer 344
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously
injected with 30 µCi

99m

Tc-EC-AMT. Blood samples were drawn through lateral tail

vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10 µL).
The blood samples were measured for radioactivity by gamma counter, and then
were calculated as percentage of the injected dose per gram of blood (%ID/g).

In vivo Tissue Distribution Studies
Tissue distribution studies of

99m

Tc-EC-AMT (study I, n=9) and

18

F-FDG (study

II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g, n=18).
For each compound, the rats were divided into three groups for three time intervals
(0.5, 2, 4 h for 99mTc-EC-AMT; 0.5, 1, 2 h for 18F-FDG; n=3/time point). The injection
activity was 25±0.5 µCi/rat intravenously. At each time interval, the rats were
sacrificed, and the selected tissues were excised, weighed and measured for
radioactivity by gamma counter. Each sample was calculated as percentage of the
injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted sample
of the original injection were used as reference.

Planar Scintigraphic Imaging Study
Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast
5

tumor cells 13762 suspension in PBS (10 cells/rat) into the right legs. Planar
scintigraphic imaging of

99m

Tc-EC-AMT was performed 12-14 days after inoculation

when tumors reached approximately 1 cm in diameter. Planar scintigraphic images
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were obtained using M-CAM (Siemens Medical Solutions, Hoffman Estates, IL)
equipped with a Low Energy High Resolution collimator. Anesthetized breast tumorbearing rats were injected intravenously with 99mTc-EC-AMT (0.3 mg/rat, 300 µCi/rat;
n=3). The images were acquired up to 4 h post-administration of tracers. Computer
outlined regions of interest (ROIs in counts per pixel) between tumor and muscle
were used to calculate tumor/muscle (T/M) ratios. Percentage of the injected dose
(%ID) of tumor was also calculated from the reference standard, which was 1/10 of
the original injection activity.

In Vivo Uptake Blocking Study
To ascertain whether 99mTc-EC-AMT uptake is mediated specifically by LAT, in
vivo blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor
was conducted. The same animal model used in the planar scintigraphic imaging
study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL saline
(pH adjusted to 2-3) was administered intravenously to mammary tumor–bearing
rats 1 h prior to

99m

Tc-EC-AMT injection. Planar scintigraphic images were acquired

up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to calculate the
ratios

of

liver/muscle,

kidney/muscle,

and

tumor/muscle,

respectively.

In

addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the
reference standard, which was 1/10 of the original injection activity. The results
were compared with those from the rats injected with 99mTc-EC-AMT alone (control).

Tumor and Inflammation Uptake Comparison In Vivo
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To investigate whether

99m

Tc-EC-AMT can differentiate tumor from the

inflammatory tissue, a rat model bearing both mammary tumor and turpentine oilinduced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was
injected into the left calf muscles of the rats to induce inflammation. The
anesthetized rats (n=3) were injected intravenously with

99m

Tc-EC-AMT 24 h after

the turpentine injection. Planar scintigraphic images were acquired up to 4 h, and
ROIs of tumor, inflammation, and muscle were used to calculate the tumor-tomuscle

ratios

(T/Ms),

inflammation-to-muscle

ratios

(I/Ms),

and

tumor-to-

inflammation ratios (T/Is), respectively. Same animal model was used to evaluate
18

F-FDG. Micro-PET imaging of

18

F-FDG was performed using R4 micro-PET

scanner (Concorde Microsystems, TN). The rats were injected intravenously with
18

F-FDG (500 uCi/rat, n=3), and dynamic PET scans were obtained for 90 min with

a spatial resolution of 2.2 mm. PET images were reconstructed by using the
ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3)
that were estimated from the average pixels within ROIs drawn around the tumor,
inflammation or muscle on transverse slices of the reconstructed image sets.

III.

Results

Chemistry
EC-AMT was synthesized via a five-step procedure. The synthetic scheme is

64

shown in Fig.3.1. The structures and purities of EC-AMT and Re-EC-AMT were
confirmed by 1H- and 13C- NMR, mass spectra, and HPLC. For EC-AMT, the 1Hand 13C-NMR results were 1H NMR (D2O, δ/ppm): 7.10 (d, 2H, phenyl ring), 6.79 (d,
2H, phenyl ring), 3.96 (dd, 2H, O-CH2), 3.09(t, 1H, CHN), 2.87 (d, 2H, PhCH2-),
2.68-2.40(m, 8H, -CH2-), 1.88(m, 2H, C-CH2-C), 1.13[s, 9H, C(CH3)3].

13

C NMR

(D2O, δ/ppm): 184.22, 180.16, 156.69, 131.11, 130.40, 114.65, 66.90, 62.69, 59.31,
57.28, 46.33, 45.47, 34.29, 28.35, 28.23, 25.76, 16.85. For Re-EC-AMT, the 1Hand

13

C-NMR results are 1H NMR (D2O, δ/ppm): 7.02 (d, 2H, phenyl ring), 6.87 (d,

2H, phenyl ring), 4.05 (t, 2H, O-CH2),3.17-3.00(m, 3H, CHN, PhCH2), 2.73-2.50 (m,
8H, -CH2-), 1.96(m, 2H, C-CH2-C), 1.38[s, 3H, CH3].
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Figure 3.1. Synthetic scheme of precursor EC-AMT and cold standard reference
compound rhenium (Re) EC-AMT.
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99m

Tc-labeled EC-AMT was obtained with high radiochemical purity (95%) (Fig.

3.2). The retention time of

99m

Tc-EC-AMT matched to that of the cold reference

standard Re-EC-AMT (Fig. 3.2). The partition coefficient value (logP) of

99m

Tc-EC-

AMT was -1.14±0.072.

Figure 3.2. High performance liquid chromatography analysis of 99mTc-EC-AMT and
Re-EC-AMT at a flow rate of 0.5 mL/min using a C-18 reverse column under UV
absorbance of 274 nm.
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In Vitro Cellular Uptake Studies
The cellular uptake kinetics of

99m

Tc-EC-AMT,

99m

Tc-EC, and

rat breast tumor cell line 13762 is shown in Fig. 3.3. The uptake of

18

F-FDG using

99m

Tc-EC-AMT

into the 13762 mammary tumor cells increased rapidly, and reached 1.85%Uptake
at 4 h. In addition, the %Uptake of

99m

Tc-EC-AMT was dramatically higher than that

of 18F-FDG and the negative control 99mTc-EC.

Figure 3.3. Time course of 99mTc-EC-AMT, 99mTc-EC and 18F-FDG uptake in rat breast
tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D. percentage of
cellular uptake (%Uptake).
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Competitive Inhibition Study of 99mTc-EC-AMT
After incubating the 13762 rat mammary tumor cells with L-tyrosine at 10-100
times as high as the concentrations of EC-AMT, these tumor cells showed a
99m

significantly decrease in
that

99m

Tc-EC-AMT uptake (Fig. 3.4). These results suggest

Tc-EC-AMT is transported at least partially via the same transporter system

LAT that L-tyrosine exploits.
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Figure 3.4. Competitive inhibition uptake of 99mTc-EC-AMT by L-tyrosine in rat breast
tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [10X–100X of
EC-AMT concentration (8 mg/well)] were used. Data are expressed in mean ± S.D.
percentage of cellular uptake (%Uptake).
*P<0.05 compared with the control group.

69

Blood Clearance
The blood clearance curve for

99m

Tc-EC-AMT in normal Fischer 344 rats (n=3)

is shown in Fig. 3.5. The plasma half-life of the distribution phase (t1/2 α) was
9.41±0.202 min, and that of the elimination phase (t1/2 β) was 98.75±5.377 min.

Figure 3.5. Blood clearance (%ID/g) of 99mTc-EC-AMT in normal female Fischer 344
rats (n=3). The data represent the mean radioactivity expressed as a percentage of
the injected dose per gram of blood ± S.D.
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In Vivo Tissue Distribution Studies
The tissue distribution results of

99m

Tc-EC-AMT and

18

F-FDG in the normal

Fischer 344 rats are shown in Tables 3.1 and 3.2, respectively. Low thyroid and
stomach uptake of

99m

Tc-EC-AMT was observed, suggesting its high stability in vivo.

Table 3.1. Biodistribution of 99mTc-EC-AMT in normal Fischer 344 female rats.

%ID/g

30 MIN

120 MIN

240 MIN

blood

0.64 ±0.047

0.41 ±0.019

0.17 ±0.004

heart

0.19 ±0.005

0.11 ±0.004

0.05 ±0.002

lung

0.44 ±0.038

0.29 ±0.012

0.14 ±0.004

thyroid

0.28 ±0.029

0.22 ±0.038

0.09 ±0.008

pancreas

0.15 ±0.016

0.10 ±0.003

0.06 ±0.001

liver

2.03 ±0.180

1.48 ±0.079

1.07 ±0.155

spleen

0.56 ±0.053

0.54 ±0.027

0.48 ±0.054

kidney

8.56 ±0.966

9.01 ±0.212

8.43 ±0.171

stomach

0.28 ±0.070

0.12 ±0.006

0.08 ±0.012

intestine

0.89 ±0.107

0.81 ±0.490

0.13 ±0.009

muscle

0.10 ±0.017

0.05 ±0.001

0.02 ±0.001

bone& joint

0.09 ±0.016

0.07 ±0.010

0.06 ±0.005

brain

0.02 ±0.003

0.02 ±0.003

0.01 ±0.001

Each rat received 99mTc-EC-AMT (25 µCi, intravenously). Each value is percent of injected
dose per gram weight (n= 3)/time interval. Each data represents mean of three
measurements with standard deviation.
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Table 3.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats.

%ID/g

30 MIN

60 MIN

blood

0.40 ±0.042

0.13 ±0.006

0.06 ±0.002

heart

1.57 ±0.056

1.38 ±0.126

1.08 ±0.068

lung

0.55 ±0.056

0.42 ±0.024

0.46 ±0.027

thyroid

1.07 ±0.080

1.04 ±0.040

1.05 ±0.069

pancreas

0.26 ±0.028

0.21 ±0.006

0.20 ±0.016

liver

0.40 ±0.048

0.16 ±0.006

0.13 ±0.012

spleen

0.82 ±0.081

0.74 ±0.032

0.86 ±0.071

kidney

0.71 ±0.051

0.37 ±0.012

0.24 ±0.018

stomach

0.61 ±0.078

0.44 ±0.031

0.39 ±0.030

intestine

0.69 ±0.068

0.53 ±0.035

0.52 ±0.025

muscle

0.33 ±0.040

0.34 ±0.027

0.74 ±0.024

bone& joint

0.33 ±0.036

0.44 ±0.065

0.50 ±0.034

brain

2.00 ±0.149

1.99 ±0.046

1.39 ±0.086

Each rat received

120 MIN

18

F-FDG (25 µCi, intravenously). Each value is percent of injected dose

per gram weight (n =3)/time interval. Each data represents mean of three measurements
with standard deviation.
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Planar Scintigraphic Imaging Study
The selected planar scintigraphic images of

99m

Tc-EC-AMT at 30 min, 2h, and

4 h in breast tumor-bearing rats are shown in Fig. 3.6. Tumors were clearly detected
by 99mTc-EC-AMT at all time-points. The T/M ratios at 30 min, 2h, and 4 h were 6.94,
8.77, and 10.59, respectively. Tumor %IDs at these three time-points were 1.87%,
1.25%, and 1.17%, respectively (Fig. 3.6).

30 MIN

120 MIN

240 MIN

T/M = 6.94

T/M = 8.77

T/M = 10.59

Tumor %ID: 1.87

Tumor %ID: 1.25

Tumor %ID: 1.17

T

Figure 3.6. Planar scintigraphy of 99mTc-EC-AMT at 30 – 240 min in rat breast tumorbearing rats (T: tumor).
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In Vivo Uptake Blocking Study
The liver, kidneys, tumor, and muscle %IDs, as well as the ratios of these
organs to muscle before and after in vivo blocking by unlabeled L-Tyrosine were
listed in Table 3.3 and 3.4. At 30 min,

99m

Tc-EC-AMT uptake in liver, kidney, and

tumor decreased by 9.8%, 47.9%, and 23.9% respectively by using the blocking
agent L-Tyrosine. However, after 90 min, no significant blocking effect was
observed. (Results at 4 h are not shown). These results suggest that 99mTc-EC-AMT
at least partially utilizes the same transport system LAT as L-Tyrosine does, and is
taken by tumor rapidly.

Table 3.3. Percentage of injected dose (%ID) of selected organs before and after in vivo
blocking of

99m

Tc-EC-AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red

font indicates the decreased %ID when compared to the corresponding control group.
Blue shading indicates P<0.05 when compared to the corresponding control group
(n=3/group/time interval).
30 min

2 hr

4hr

%ID
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver

6.98±0.44

6.91±0.56

1.00%

8.02±0.21

6.47±0.16

19.33%

6.66±0.53

5.41±0.15

18.77%

Kidney

28.0±1.6

16.0±2.6

42.86%

34.2±3.6

25.3±4.0

26.02%

23.5±1.7

20.2±0.6

14.04%

Tumor

1.28±0.04

1.07±0.09

16.41%

0.77±0.08

0.74±0.05

3.90%

0.68±0.09

0.70±0.11

-2.94%

Muscle

0.28±0.03

0.30±0.03

-7.14%

0.21±0.03

0.20±0.04

4.76%

0.13±0.01

0.13±0.02

0.00%
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Table 3.4. Selected organ to muscle ratios before and after in vivo blocking of

99m

Tc-EC-

AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the
decreased %ID when compared to the corresponding control group. Blue shading
indicates P<0.05 when compared to the corresponding control group (n=3/group/time
interval).
30 min

2 hr

4hr

Ratio
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver/Muscle

25.4±1.8

22.9±1.5

9.84%

38.7±1.8

34.7±0.9

10.34%

50.6±3.3

41.5±2.1

26.90%

Kidney/Muscle

101.8±1.7

53.0±1.2

47.94%

165.3±5.7

135.9±10.3

17.79%

178.7±14.4

154.5±6.9

8.19%

Tumor/Muscle

4.64±0.54

3.54±0.32

23.71%

3.74±0.16

3.70±0.23

1.07%

5.15±0.17

5.33±0.41

-7.52%
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Tumor and Inflammation Uptake Comparison In Vivo
The representative planar scintigraphic images of
the micro-PET images of

99m

Tc-EC-AMT, as well as

18

F-FDG in breast tumor and inflammation-bearing rats

are shown in Fig. 3.7 and Fig. 3.8, respectively. The T/M of

99m

Tc-EC-AMT at each

time-point was relatively lower than I/M ratio. Furthermore, the T/I of
was also lower than that of

18

F-FDG. These results suggested that

99m

Tc-EC-AMT

99m

Tc-EC-AMT

could not differentiate tumor from inflammation very well in this tumor model.

30 MIN

120 MIN

240 MIN

I

T

T/M
I/M
T/I

30 min
2.68
3.17
0.84

2 hr
2.51
3.10
0.81

4 hr
2.75
3.02
0.91

Figure 3.7. Planar scintigraphic images of 99mTc-EC-AMT at 30 – 240 min in rat breast
tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle
ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios
(T/Is) are listed below the figure.
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Transverse

T

Saggital

Axial

I
T

T

I

I

30 min

60 min

90 min

T/M
I/M
T/I

30 min

60 min

90 min

5.88

7.54

4.90

3.43

3.77

2.72

1.71

1.99

1.80

Figure 3.8. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is)
are listed below the figure.
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IV.

Discussion
The present study investigated the imaging capability of

99m

Tc-EC-AMT in

breast tumor models in vitro and in vivo. For chemical synthesis, the precursor ECAMT was successfully synthesized with an overall yield of 23%. Since the chelator
EC was unprotected during the coupling reaction with AMT, each EC molecule
could be conjugated with more than one AMT. Moreover, AMT might not only be
conjugated with EC specifically on the nitrogen atom, but also on the sulfur atom.
Those two potential problems could be readily solved by conducting the coupling
reaction in the mild aqueous solution instead of the organic one. In addition, the
molar ratio of EC and N-t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine
ethylester (compound 3) was controlled accurately in 2:1 under this aqueous
solution. Furthermore, the structure of EC-AMT was well confirmed from the 1HNMR and mass spectra results.
When label the precursor EC-AMT with
95%. In respect that

99m

99m

Tc, the radiochemical purity was

Tc-EC-AMT is a kit-product and labeled without any further

purification, the radiochemical yield was assumed to be identical to its
radiochemical purity (95%). Re-EC-AMT was synthesized as the reference standard
for the structure confirmation of

99m

Tc-EC-AMT. In periodic table, Tc is a second-

row transition element in Group 7 and right above rhenium. Hence, Tc is very
similar to Re in terms of chemistry, and they are known to have identical
coordination parameters with the same ligand such as AMT[103]. From the HPLC
results, the retention time of

99m

Tc-EC-AMT matched to that of Re-EC-AMT,

suggested the radiochemical structure of

78

99m

Tc-EC-AMT was correct. In addition,

one radioisotopic form of Re,

188

Re, is commonly used for the internal radionuclide

therapy[132]. Therefore, 188Re-EC-AMT might be valuable in the treatment of breast
cancer, while

99m

Tc-EC-AMT could be used to diagnose the cancer and monitor

treatment response in the future.
In cellular uptake study,

99m

tumor cells, and the %Uptake of

Tc-EC-AMT was taken up rapidly by rat mammary
99m

Tc-EC-AMT was significantly higher than that of

the negative control 99mTc-EC, suggesting high specificity of 99mTc-EC-AMT in tumor
uptake. Besides,

99m

Tc-EC-AMT has much higher uptake than

vitro breast cancer model. In competitive inhibition study,

99m

18

F-FDG in this in

Tc-EC-AMT uptake

could be significantly inhibited by L-tyrosine, which suggests that

99m

Tc-EC-AMT is

transported at least partially via the same transporter system LAT that L-tyrosine
exploits. Our findings were consistent with other reported studies regarding
radiolabeled tyrosine analogs. For instance,
AMT[56, 120],

11

C/14C-tyrosine[119],

123 125

I/

I-labeled

18

F-labeled tyrosine[121], AMT[76], and fluoroethyltyrosine (18F-FET)

[114] have been proven to be predominantly transported via amino acid transporter
LAT. Increased expression level of LAT has been observed in various types of
tumors[38], therefore, upregulated LAT is a suitable target for tumor imaging.
For in vivo evaluation,

99m

Tc-EC-AMT had a relatively fast blood clearance in

normal Fischer 344 rats (Fig. 3.5). Biodistribution study showed that

99m

Tc-EC-AMT

had high uptake in kidneys of normal rats (Table 3.1), which was consistent with the
imaging results of breast tumor-bearing rats (Fig. 3.6).This may due to the
characteristics of EC given that

99m

Tc-EC is a well-known renal tubular imaging

agent[122]. In addition, Moore et al. reported that AMT itself, an inhibitor of tyrosine
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hydroxylase, could not be excreted from kidneys and hence crystallized in the
proximal tubules because of its poor solubility at the hydrogen ion concentrations of
body fluids (pH 5-8)[133]. Furthermore, Shikano et al. confirmed that the uptake of
123

I-labeled AMT (123I-AMT) into normal human renal proximal tubule epithelial cells

could be significantly inhibited by BCH, an LAT specific inhibitor[123]. This result
suggests that LAT is involved in
99m

123

I-AMT uptake in kidneys. To ascertain whether

Tc-EC-AMT uptake is mediated specifically by LAT, we then conducted in vivo

uptake blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor
99m

(Table 3.3 and 3.4).

Tc-EC-AMT uptake in liver, kidney, and tumor were

significantly blocked at early time-points, which suggested that both

99m

Tc-EC-AMT

and unlabeled L-Tyrosine were rapidly uptaken via amino acid transporter LAT.
These in vivo findings were coherent with the in vitro competitive inhibition results.
In planar imaging studies shown in Fig. 3.6, tumors could be clearly detected
by 99mTc-EC-AMT at all time-points. Because of the washout of non-specific uptake,
T/M ratios of

99m

Tc-EC-AMT increased from 6.94 to 10.59, which were even much

higher than those of

18

F-FDG. The T/M ratios of

18

F-FDG in the same animal model

were 5.88, 7.54 and 2.87 for 30 min, 60 min and 120 min, respectively (images not
shown). Nevertheless, we found that

99m

Tc-EC-AMT was not superior to

18

F-FDG in

differentiating tumor from inflammation in this animal model because the T/Is of
99m

Tc-EC-AMT were lower than those of

18

F-FDG. In this study, we used turpentine

to induce inflammation chemically. In future, we may need to create and test

99m

Tc-

EC-AMT in another animal model using radiation to induce inflammation so it can
more similarly mimic the patients undergoing radiation therapy.
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In summary, EC-AMT was synthesized and labeled with

99m

Tc readily and

efficiently with high radiochemical purity. In vitro cellular uptake study demonstrated
that

99m

Tc-EC-AMT transport involved amino acid transporter system LAT. Although

it cannot differentiate breast tumor from chemical-induced inflammation very well,
99m

Tc-EC-AMT has great potential for breast cancer imaging given its simple

chemical synthesis procedure, more cost effectiveness of the isotope, and high
tumor/muscle uptake ratios in planar imaging. By taking the advantages of the
coordination capability of the chelator, EC-AMT could chelate various radioisotopes
for either imaging or therapy in the future.
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CHAPTER 4

Development of

99m

Tc-N4-Tyrosine for breast cancer

imaging
I.

Introduction
18

18

F-FDG, an

F-labeled glucose analog, is a gold standard for PET in cancer

diagnosis[2]. However,

18

F-FDG-PET has several limitations that give rise to false

positive/negative diagnosis and poor predictive value of tumor response to
chemo/radio therapy[125]. For instance,

18

F-FDG cannot distinguish tumor from

inflammatory or normal brain tissues because both sites have high glucose
consumption. Therefore, radiolabeled amino acids have been developed as an
alternative to

18

F-FDG. Their use in tumor detection is based on an increased

uptake of amino acids in tumor cells, which is assumed to reflect an enhanced
amino acid transporter, metabolism, and protein synthesis[114]. Among all
radiolabeled amino acids, aromatic ones such as tyrosine and its derivatives are
more suitable given their easier chemistry alterations and favorable biological
characterizations. To date, tyrosine and its α-methyl substituted analog AMT have
been successfully labeled with
imaging, as well as

11

C[115, 116],

18

F[75, 81] and

124/125

I[65] for PET

123/131

I[56] for SPECT imaging, respectively. Most of those

radiolabeled tyrosine analogs show promising preclinical and clinical results in
tumor imaging, especially in brain tumor diagnosis. In addition, they have been
proven to accumulate into the tumor cells predominantly via LAT, which is the only
system that can transport large neutral amino acids with aromatic rings such as
tyrosine, phenylalanine, and tryptophan[38, 41]. LAT, especially its subtype LAT1, is
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an ideal target for tumor imaging because it is up-regulated and highly expressed in
many cancer cell lines and correlated with tumor growth[117, 118].
Although the existing radiolabeled tyrosine and its derivatives have shown very
promising clinical outcomes, most of them require an on-site cyclotron to produce
the radioisotope, which is inconvenient and expensive. Besides, the half-life of the
radioisotopes are either too short (i.e. 20 min for

11

C) or too long (i.e. 57.4 days for

125

I). Furthermore, iodine-labeled compounds are not stable in vivo because of

deiodination. So far,

18

radiosynthesis yield of

F has the most appropriate half-life (110 min), however, the
18

F-labeled radiotracers appear to be relatively low because

of its electrophillic fluorination and tedious purification. Therefore, it is desirable to
develop a radiotracer with simpler chemistry and affordable isotope, which can be
used clinically in most major medical facilities.

99m

Tc is an ideal radioisotope for

diagnostic imaging studies, due to its physical characteristics. It emits a 140 keV
gamma ray in 89% abundance [103], which is commonly used by gamma imaging
and SPECT. The half-life of

99m

Tc is 6.02 h, which can provide serial images and

therefore overcome the drawback of

18

F. Unlike most of the cyclotron-produced

radionuclides that utilize the covalent chemistry for labeling,

99m

Tc requires a

“chelator” to conjugate the radioisotope with the target ligand. The nitrogen, oxygen
and sulfur combination have been shown to be stable chelators for 99mTc such as N4
(e.g. DOTA, cyclam-14), N3S (e.g. MAG-3), N2S2 (e.g. ECD), NS3, S4 (e.g. sulfur
colloid), diethylenetriamine pentaacetic acid (DTPA), O2S2 (e.g. DMSA), and
hydrazinenicotinamide (HYNIC)[68, 101-105]. By taking the advantage of using the
chelator, we could label several other radioisotopes such as Gallium-68, Indium-111,
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or Rhenium-188 with the same ligand for diagnostic and therapeutic applications in
future[105, 107]. Here, we report the synthesis of

99m

Tc-labeled tyrosine using N4

cyclam as a chelator and evaluate its potential in breast tumor imaging.

II.

Materials and methods

Chemicals and Analysis
All chemicals and sources used here were previously described in Chapter 2.

Synthesis of Precursor N4-Tyrosine
a)

N-t-Butoxycarbonyl-O-[3-Br-propyl]-L-tyrosine methyl ester 1.
N-t-Butoxycarbonyl-L-tyrosine methyl ester (25 g; 0.085 mol) was dissolved in

acetone (300 mL). 1,3-dibromopropane (17.3 mL; 0.169 mol) and K2CO3 (58 g;
0.420 mol) were added under nitrogen. The reaction mixture was refluxed at 80 oC
overnight. After cooling and filtration, the solvent was removed under reduced
pressure, and the residue was dissolved in chloroform. The residue was washed
with water and dried with anhydrous MgSO4. The product was purified by column
chromatography using a silica gel column, eluted with hexane/ethyl acetate (2:1 v/v)
to yield 33.3 g (94.6%). Ms (m/z): 440.09 [M+Na]+.

b)

N1, N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane (N1,N4-cyclooxamide)

2.
N4 cyclam (15.00 g; 74.88 mmol) was dissolved in 150 mL of anhydrous
ethanol, and diethyl oxalate (10.94 g; 74.88 mmol) was added. The reaction mixture
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was refluxed 18 h at 75 0C. The solvent was rotary evaporated and the crude
product was recrystallized in acetone : ethanol to yield white crystals of N1,N4dioxylyl-1,4,8,11-1,5,8,12-tetraazabicyclotetradecane (N1,N4-cyclooxamide) 2 . Yield:
13.64 g (17.31 mmol, 72.00 %). Ms (m/z) = 255.33 [M]+.

c)

N-t-Butoxycarbonyl-O-[3-( N1,N4-dioxylyl-1,4,8,11-

tetraazabicyclotetradecane)-propyl]- tyrosine methylester 3.
Compound 2 (0.625 g; 2.46 mmol) was dissolved in 20 mL of anhydrous DMF
and reacted with a solution of compound 1 (1.06 g; 2.46 mmol) in 40 mL of DMF
under nitrogen atmosphere. The mixture was refluxed at 75 0C for 18 hours, and
then cooled to room temperature. The solvent was removed in vacuo. The residue
was dissolved in 30 mL chloroform, washed with water and 12 mL of 1M Na2CO3,
and then separated for the organic layer. The crude compound was purified via a
silica gel column using chloroform: methanol (9:1) solution. Yield: 0.6489 g (1.052
mmol, 42.76%).

d)

O-[3-(N1,N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane)-propyl]-

tyrosine methylester 4.
Compound 3 (0.6 g; 1 mmol) was dissolved in anhydrous dichloromethane (15
mL), and 2.5 mL of trifluoroacetic acid was added. The solution was stirred
overnight at room temperature, and the solvents were removed in vacuo.
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e)

O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-tyrosine (N4-

Tyrosine) 5.
Compound 4 (0.25 g; mmol) was dissolved in 5 mL water, and 2.5 mL of 10N
NaOH was added to it. The solution was stirred and refluxed overnight at 90 0C, and
the solvent was evaporated in vacuo. The crude compound was then dissolved in 5
mL water, and pH of the solution was neutralized to pH=7 by adding 5 M HCl. The
final solution was lyophilized overnight to obtain white powder, which was then
dissolved in 25 mL anhydrous methanol, filtered, evaporated, and lyophilized to
obtain off-white powder.

Radiolabeling of N4-Tyrosine with 99mTc
N4-Tyrosine (1 mg) was dissolved in 0.2 mL sterile water, followed by adding
tin (II) chloride (0.1 mL, 1 mg/mL). Required amount of Na99mTcO4 was added to
N4-Tyrosine solution. Radiochemical purity was determined by radio-HPLC (Waters,
Milford, MA), eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min.

Determination of the Partition Coefficient
To determine the lipophilicity, 20 µL of

99m

Tc-N4-Tyrosine was added into an

equal volume mixture of 1-octanol and sterile water in a centrifuge tube. The
mixture was vortexed at room temperature for 1 min and then centrifuged at 5000
rpm for 5 min. From each phase, 0.1 mL of the aliquot was taken out and the
radioactivity was measured by gamma counter (Cobra Quantum; Packard, MN).
The measurement was repeated for three times, and care was taken to avoid cross
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contamination between the phases. The partition coefficient value, expressed as
logP, was calculated using the following equation:
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer)

In Vitro Cellular Uptake Studies
Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville,
MD) was selected because the same cell line was used to create the animal model
for in vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium
and nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in
a humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue
culture plates (2x105 cells/well) and incubated with
8 uCi/well),

99m

99m

Tc-N4 (0.025 mg/well, 8 uCi/well) or

Tc-N4-Tyrosine (0.05 mg/well,

18

F-FDG (8 uCi/well) for 0-4 h.

After incubation, cells were washed with ice-cold PBS twice and detached by
treating them with 0.5 mL of trypsin for 5 min. Cells were then collected and the
radioactivity was measured with gamma counter (Cobra Quantum; Packard, MN).
Data were expressed in mean ±S.D. percent of cellular uptake (%Uptake) in
triplicate.

In Vitro Competitive Inhibition Study
To investigate the transport mechanisms of

99m

Tc-N4-Tyrosine, the competitive

inhibition study using L-tyrosine was conducted. Rat breast tumor cells were coincubated with 99mTc-N4-Tyrosine (8 µg/well, 8 µCi/well) and L-tyrosine for up to 1 h.
A set of concentrations of L-tyrosine (10-1000x of the N4-Tyrosine concentration)
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were used. After incubation, cells were washed with ice-cold PBS twice and
detached by treating them with 0.5 mL of trypsin for 5 min. Cells were then collected
and the radioactivity was measured by gamma counter. Data were expressed in
mean ±S.D. percent of cellular uptake (%Uptake) in triplicate.

Blood Clearance
All animal work was carried out in the Small Animal Imaging Facility (SAIF) at
UTMDACC under a protocol approved by Institutional Animal Care and Use
Committee (IACUC). For blood clearance analysis, three normal female Fischer 344
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously
injected with 30 µCi

99m

Tc-N4-Tyrosine. Blood samples were drawn through lateral

tail vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10
µL). The blood samples were measured for radioactivity by gamma counter, and
then were calculated as percentage of the injected dose per gram of blood (%ID/g).

In vivo Tissue Distribution Studies
Tissue distribution studies of

99m

Tc-N4-Tyrosine (study I, n=9) and

18

F-FDG

(study II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g,
n=18). For each compound, the rats were divided into three groups for three time
intervals (0.5, 2, 4 h for

99m

Tc-N4-Tyrosine; 0.5, 1, 2 h for

18

F-FDG; n=3/time point).

The injection activity was 25±0.5 µCi/rat intravenously. At each time interval, the
rats were sacrificed, and the selected tissues were excised, weighed and measured
for radioactivity by gamma counter. Each sample was calculated as percentage of
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the injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted
sample of the original injection were used as reference.

Planar Scintigraphic Imaging Study
Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast
5

tumor cells 13762 suspension in PBS (10 cells/rat) into the right legs. Planar
scintigraphic imaging of

99m

Tc-N4-Tyrosine was performed 12-14 days after

inoculation when tumors reached approximately 1 cm in diameter. Planar
scintigraphic images were obtained using M-CAM (Siemens Medical Solutions,
Hoffman Estates, IL) equipped with a Low Energy High Resolution collimator.
Anesthetized breast tumor-bearing rats were injected intravenously with

99m

Tc-N4-

Tyrosine (0.3 mg/rat, 300 µCi/rat; n=3). The images were acquired up to 4 h postadministration of tracers. Computer outlined regions of interest (ROIs in counts per
pixel) between tumor and muscle were used to calculate tumor/muscle (T/M) ratios.
Percentage of the injected dose (%ID) of tumor was also calculated from the
reference standard, which was 1/10 of the original injection activity.

In Vivo Uptake Blocking Study
To ascertain whether

99m

Tc-N4-Tyrosine uptake is mediated specifically by

LAT, in vivo blocking studies using the unlabeled L-Tyrosine as the competitive
inhibitor was conducted. The same animal model used in the planar scintigraphic
imaging study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL
saline (pH adjusted to 2-3) was administered intravenously to mammary tumor–
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bearing rats 1 h prior to

99m

Tc-N4-Tyrosine injection. Planar scintigraphic images

were acquired up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to
calculate the ratios of liver/muscle, kidney/muscle, and tumor/muscle, respectively.
In addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the
reference standard, which was 1/10 of the original injection activity. The results
were compared with those from the rats injected with

99m

Tc-N4-Tyrosine alone

(control).

Tumor and Inflammation Uptake Comparison In Vivo
To investigate whether

99m

Tc-N4-Tyrosine can differentiate tumor from the

inflammatory tissue, a rat model bearing both mammary tumor and turpentine oilinduced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was
injected into the left calf muscles of the rats to induce inflammation. The
anesthetized rats (n=3) were injected intravenously with

99m

Tc-N4-Tyrosine 24 h

after the turpentine injection. Planar scintigraphic images were acquired up to 4 h,
and ROIs of tumor, inflammation, and muscle were used to calculate the tumor-tomuscle

ratios

(T/Ms),

inflammation-to-muscle

ratios

(I/Ms),

and

tumor-to-

inflammation ratios (T/Is), respectively. Same animal model was used to evaluate
18

F-FDG. Micro-PET imaging of

18

F-FDG was performed using R4 micro-PET

scanner (Concorde Microsystems, TN). The rats were injected intravenously with
18

F-FDG (500 µCi/rat, n=3), and dynamic PET scans were obtained for 90 min with
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a spatial resolution of 2.2 mm. PET images were reconstructed by using the
ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3)
that were estimated from the average pixels within ROIs drawn around the tumor,
inflammation or muscle on transverse slices of the reconstructed image sets.

III.

Results

Chemistry and Radiochemistry
Precursor N4-Tyrosine was synthesized via a five-step procedure and the total
synthesis yield was 38%. The synthetic scheme is shown in Fig.4.1. The structure
and purity of N4-Tyrosine was confirmed by 1H- and 13C- NMR, mass spectra, and
HPLC. The 1H- and

13

C-NMR results were 1H- NMR (D2O, δ/ppm): 7.18 (d, 2H,

phenyl ring), 6.95 (d, 2H, phenyl ring), 4.073 (t, 2H, O-CH2), 3.43(t, 1H, CHN), 2.283.00 (m, 2OH, OCH2 and NCH2-), 1.87-1.91(m, 2H, C-CH2-C), 1.68-1.79(m, 4H, CCH2-C).

13

C- NMR (D2O, δ/ppm):162.88,156.72, 130.76, 117.57, 115.25, 68.55,

57.29, 53.91, 51.56, 49.95, 49.17, 48.96, 48.24, 48.03, 46.80, 45.73, 45.35, 39.27,
24.90, 24.31, 23.87.
Precursor N4-Tyrosine could be labeled with

99m

Tc successfully in a high

radiochemical purity (>96%). The logP of 99mTc-N4-Tyrosine was -2.83±0.082.
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Figure 4.1. Synthetic scheme of precursor N4-Tyrosine.
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In Vitro Cellular Uptake Studies
The cellular uptake kinetics of

99m

Tc-N4-Tyrosine,

99m

Tc-N4, and

18

F-FDG

using rat breast tumor cells is shown in Fig. 4.2. There was a drastically increased
uptake for

99m

Tc-N4-Tyrosine at 15-240 min, but not for

which suggested that

99m

99m

Tc-N4 chelator itself,

Tc-N4-Tyrosine can enter and accumulate into tumor cells

rapidly and specifically. In addition, the %Uptake of

99m

Tc-N4-Tyrosine was

relatively higher than that of 18F-FDG.

0.900
99mTc-N4-Tyrosine
0.800

18F-FDG
99mTc-N4

0.700

%Uptake

0.600
0.500
0.400
0.300
0.200
0.100
0.000
0
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90

120
Time (min)

150

180

210

240

Figure 4.2. Time course of 99mTc-N4-Tyrosine, 99mTc-N4 and 18F-FDG uptake in rat
breast tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D.
percentage of cellular uptake (%Uptake).
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Competitive Inhibition Study of 99mTc-N4-Tyrosine
After co-incubated with L-tyrosine at 10-1000 times as high as the
concentrations of N4-Tyrosine,

99m

Tc-N4-Tyrosine did not show any significantly

decreased uptake at all concentrations. The

99m

Tc-N4-Tyrosine uptakes of selected

concentrations are shown in Fig. 4.3. These results suggest that

99m

Tc-N4-Tyrosine

may not share the same LAT transporter system as L-Tyrosine.

1.100
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0.900
0.800
0.700

99mTc-N4-Tyrosine

% Uptake
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0.600
200x
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0.200
0.100
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0

15
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45
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Figure 4.3. Competitive inhibition uptake of 99mTc-N4-Tyrosine by L-tyrosine in rat
breast tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [150-300X
of N4-Tyrosine concentration (8 mg/well)] were used. Data are expressed in mean ±
S.D. percentage of cellular uptake (%Uptake).
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Blood Clearance
The blood clearance curve for

99m

Tc-N4-Tyrosine in normal Fischer 344 rats

(n=3) is shown in Fig. 4.4. The plasma half-life of the distribution phase (t1/2 α) was
9.31±0.759 min, and that of the elimination phase (t1/2 β) was 90.14±1.901 min.
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2.500
2.000
1.500
1.000
0.500
0.000
0

120

240

360
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600

720
840
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1080

1200

1320

1440

Figure 4.4. Blood clearance (%ID/g) of 99mTc-N4-Tyrosine in normal female Fischer
344 rats (n=3). The data represent the mean radioactivity expressed as a percentage
of the injected dose per gram of blood ± S.D.
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In Vivo Tissue Distribution Studies
The tissue distribution results of 99mTc-N4-Tyrosine and

18

F-FDG in the normal

Fischer 344 rats are shown in Tables 4.1 and 4.2, respectively. Low thyroid and
stomach uptake of

99m

Tc-N4-Tyrosine was observed, suggesting its high stability in

vivo.

Table 4.1. Biodistribution of 99mTc-N4-Tyrosine in normal Fischer 344 female rats.

30 MIN

%ID/g

120 MIN

240 MIN

blood

0.88 ±0.040

0.20 ±0.018

0.17 ±0.009

heart

0.21 ±0.022

0.06 ±0.003

0.05 ±0.003

lung

0.50 ±0.023

0.19 ±0.011

0.14 ±0.006

thyroid

0.34 ±0.019

0.10 ±0.010

0.09 ±0.006

pancreas

0.17 ±0.017

0.07 ±0.012

0.05 ±0.002

liver

1.15 ±0.059

0.70 ±0.040

0.67 ±0.044

spleen

0.94 ±0.089

0.76 ±0.032

0.63 ±0.051

kidney

11.05 ±0.783

12.34 ±0.502

12.40 ±0.405

stomach

0.20 ±0.018

0.08 ±0.003

0.06 ±0.002

intestine

0.34 ±0.057

0.13 ±0.010

0.11 ±0.006

muscle

0.07 ±0.007

0.03 ±0.002

0.02 ±0.001

bone& joint

0.24 ±0.021

0.15 ±0.008

0.12 ±0.008

brain

0.03 ±0.001

0.02 ±0.001

0.01 ±0.001

Each rat received

99m

Tc-N4-Tyrosine (25 µCi, intravenously). Each value is percent of

injected dose per gram weight (n= 3)/time interval. Each data represents mean of three
measurements with standard deviation.
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Table 4.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats.

%ID/g

30 MIN

60 MIN

blood

0.40 ±0.042

0.13 ±0.006

0.06 ±0.002

heart

1.57 ±0.056

1.38 ±0.126

1.08 ±0.068

lung

0.55 ±0.056

0.42 ±0.024

0.46 ±0.027

thyroid

1.07 ±0.080

1.04 ±0.040

1.05 ±0.069

pancreas

0.26 ±0.028

0.21 ±0.006

0.20 ±0.016

liver

0.40 ±0.048

0.16 ±0.006

0.13 ±0.012

spleen

0.82 ±0.081

0.74 ±0.032

0.86 ±0.071

kidney

0.71 ±0.051

0.37 ±0.012

0.24 ±0.018

stomach

0.61 ±0.078

0.44 ±0.031

0.39 ±0.030

intestine

0.69 ±0.068

0.53 ±0.035

0.52 ±0.025

muscle

0.33 ±0.040

0.34 ±0.027

0.74 ±0.024

bone& joint

0.33 ±0.036

0.44 ±0.065

0.50 ±0.034

brain

2.00 ±0.149

1.99 ±0.046

1.39 ±0.086

Each rat received

120 MIN

18

F-FDG (25 µCi, intravenously). Each value is percent of injected dose

per gram weight (n =3)/time interval. Each data represents mean of three measurements
with standard deviation.
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Planar Scintigraphic Imaging Study
The selected planar scintigraphic images of

99m

Tc-N4-Tyrosine at 30 min, 2h,

and 4 h in breast tumor-bearing rats are shown in Fig. 4.5. Tumors could be clearly
detected by

99m

Tc-N4-Tyrosine at all time-points. The T/M ratios at 30 min, 2h, and

4 h were 5.12, 4.88, and 5.20, respectively. Tumor %ID at these three time-points
were 1.82%, 1.87%, and 1.71%, respectively (Fig. 4.5).

30 MIN

120 MIN

240 MIN

T

T/M = 5.12
Tumor %ID: 1.82

T/M = 4.88
Tumor %ID: 1.87

T/M = 5.20
Tumor %ID: 1.71

Figure 4.5. Planar scintigraphy of 99mTc-N4-Tyrosine at 30 – 240 min in rat breast
tumor-bearing rats (T: tumor).
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In Vivo Uptake Blocking Study
The liver, kidneys, tumor, and muscle %ID of 99mTc-N4-Tyrosine, as well as the
ratios of these organs to muscle before and after in vivo blocking by unlabeled LTyrosine were listed in Table 4.3 and 4.4. By using the blocking agent L-Tyrosine,
only kidneys uptake of

99m

Tc-N4-Tyrosine decreased at all time-points. The uptake

(%ID) in liver, tumor and muscle even increased significantly. These results suggest
that

99m

Tc-N4-Tyrosine may not utilize the same transport system LAT as L-

Tyrosine does in vivo.

Table 4.3. Percentage of injected dose (%ID) of selected organs before and after in vivo
blocking of

99m

Tc-N4-Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats.

Red font indicates the decreased %ID when compared to the corresponding control
group. Blue shading indicates P<0.05 when compared to the corresponding control
group (n=3/group/time interval).
30 min

2 hr

4hr

%ID
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver

8.76±0.42

9.59±0.62

-9.47%

9.69±0.5

10.24±0.36

-5.68%

7.9±0.42

10.1±1.5

-27.85%

Kidney

26.8±3.3

19.7±0.8

26.49%

30.7±2.1

26.0±2.4

15.31%

29.8±1.7

28.6±3.7

4.03%

Tumor

0.78±0.04

1.43±0.15

-83.33%

0.34±0.03

0.72±0.03

-111.76%

0.20±0.02

0.47±0.02

-135.01%

Muscle

0.15±0.03

0.31±0.01

-106.67%

0.08±0.01

0.13±0.02

-62.50%

0.06±0.01

0.09±0.015

50.00%
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Table 4.4. Selected organ to muscle ratios before and after in vivo blocking of

99m

Tc-N4-

Tyrosine by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the
decreased %ID when compared to the corresponding control group. Blue shading
indicates P<0.05 when compared to the corresponding control group (n=3/group/time
interval).
30 min

2 hr

4hr

Ratio
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver/Muscle

57.6±3.8

30.7±2.4

46.70%

117.1±4.7

80.6±2.5

31.17%

126.1±4.2

114.1±4.5

9.52%

Kidney/Muscle

176.0±7.1

63.3±3.6

64.03%

371.4±11.6

204.6±6.8

44.91%

473.5±14.1

321.6±3.7

32.08%

Tumor/Muscle

5.12±0.34

4.57±0.12

10.74%

4.11±0.18

5.68±0.39

-38.20%

3.24±0.25

5.34±0.13

-64.81%
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Tumor and Inflammation Uptake Comparison In Vivo
The selected planar scintigraphic images of
micro-PET images of

99m

Tc-N4-Tyrosine, as well as the

18

F-FDG in breast tumor and inflammation-bearing rats are

shown in Fig. 4.6 and Fig. 4.7, respectively. The T/M of

99m

Tc-N4-Tyrosine at each

time interval was relatively higher than I/M. Although T/I at all time-points were
above 1, which meant tumor had higher uptake than the inflammation site, the ratios
were lower than those of

18

F-FDG. Therefore, these results suggested that

99m

Tc-

N4-Tyrosine could not differentiate tumor from inflammation very well.

30 MIN

120 MIN

240 MIN

I
T

T/M
I/M
T/I

30 min

2 hr

4 hr

5.12
4.26
1.20

4.11
3.62
1.14

3.24
2.45
1.32

Figure 4.6. Planar scintigraphic images of 99mTc-N4-Tyrosine at 30 – 240 min in rat
breast tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-tomuscle ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-toinflammation ratios (T/Is) are listed below the figure.
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Transverse

T
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T/M
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T/I

30 min

60 min
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5.88

7.54

4.90

3.43

3.77

2.72
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1.99

1.80

Figure 4.7. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is)
are listed below the figure.
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IV.

Discussion
In the present study, we report the synthesis of

99m

Tc-labeled tyrosine using

N4 cyclam as a chelator and evaluate its potential in breast cancer diagnosis by
using the breast tumor models in vitro and in vivo.
For chemical synthesis, the precursor N4-Tyrosine was successfully
synthesized via a five-step procedure with an overall yield of 38%. Since the starting
material N-t-Butoxycarbonyl-L-tyrosine methyl ester was commercially available, the
synthetic yield of N4-Tyrosine was much higher than that of its α-methyl derivative
N4-AMT (14%). When the precursor N4-Tyrosine was labeled with
radiochemical purity was more than 96%. Since

99m

99m

Tc, the

Tc-N4-Tyrosine is a kit-product

and labeled without any further purification, the radiochemical yield was assumed to
be identical to its radiochemical purity. As expected, the partition coefficient value
(logP) of

99m

Tc-N4-Tyrosine was lower than that of its α-methyl derivative

99m

Tc-N4-

AMT (-2.83±0.082 vs. -2.02±0.168). As we know, the lower logP indicates the lower
lipophilicity of the compound. The result verified our hypothesis that the lipophilicity
of Tyrosine-based radiotracer could be increased by adding a methyl group on its αcarbon.
In cellular uptake study,

99m

Tc-N4-Tyrosine was taken up rapidly by rat

mammary tumor cells, and the %Uptake of
higher than that of the negative control
99m

99m

Tc-N4-Tyrosine was significantly

Tc-N4, suggesting high specificity of

Tc-N4-Tyrosine in tumor uptake. Besides,

uptake than

99m

99m

Tc-N4-Tyrosine has even higher

18

F-FDG in this in vitro breast cancer model. In competitive inhibition

study using the same cell line,

99m

Tc-N4-Tyrosine uptake could not be inhibited by
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L-Tyrosine at any concentration. Its uptake even increased by adding unlabeled LTyrosine. Same results were observed in the in vivo uptake blocking studies using
the unlabeled L-Tyrosine as the competitive inhibitor (Table 4.3 and 4.4). By using
the blocking agent L-Tyrosine, only kidneys uptake of

99m

Tc-N4-Tyrosine decreased

at all time-points. The uptake (%ID) in liver, tumor and muscle even increased
significantly. Taken the in vitro and in vivo findings together, we conclude that
99m

Tc-N4-Tyrosine may not be transported by the same amino acid transporter LAT

as L-tyrosine.
99m

Tc-N4-Tyrosine had a very fast blood clearance in normal Fischer 344 rats

(Fig. 4.4). Biodistribution study showed that

99m

Tc-N4-Tyrosine had high uptake in

kidneys of normal rats (Table 4.1), which was consistent with the imaging findings in
the breast tumor-bearing rats (Fig. 4.5). This may due to the low lipophilicity of
99m

Tc-N4-Tyrosine. In addition, it might be the characteristics of tyrosine because

the similar results were also observed in our previously developed tyrosine-based
radiotracer 99mTc-EC-AMT and 99mTc-EC-Tyrosine.
In planar imaging studies shown in Fig. 4.5, tumors could be clearly detected
by 99mTc-N4-Tyrosine at all time-points; however, 99mTc-N4-Tyrosine appeared to be
not ideal for differentiation of tumor from inflammation. Although T/Is were above 1
at all time-points, which meant tumor had higher uptake than the inflammatory
tissue, the ratios were less than those of

18

F-FDG. In this study, we used turpentine

to induce inflammation chemically. In future, we may need to test 99mTc-N4-Tyrosine
in another animal model using the radiation to induce inflammation so it can more
similarly mimic the patients undergoing radiation therapy.
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In summary, N4-Tyrosine was synthesized and labeled with

99m

Tc readily and

efficiently with high radiochemical purity. Although in vitro and in vivo findings
suggest that

99m

Tc-N4-Tyrosine does not use LAT system to enter the tumor lesion,

it has high tumor/muscle uptake ratios and can detect breast tumor clearly.
Furthermore, it is not suitable to use

99m

Tc-N4-Tyrosine to distinguish breast tumor

from chemical-induced inflammation, however, we need to test its imaging potential
in other inflammation models.
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CHAPTER 5

Development of

99m

Tc-N4-AMT for breast cancer

imaging (adapted partially from[134])
I.

Introduction
18

F-FDG, an

18

F-labeled glucose analog, is the most common radiotracer for

PET in cancer diagnosis[2]. However,
practice, e.g.

18

F-FDG-PET has several limitations in

18

F-FDG cannot distinguish tumor from inflammatory or normal brain

tissues. Therefore,

18

F-labeled amino acid-based radiotracers have been reported

as an alternative, which is based on the fact that tumor cells take up and consume
more amino acids to maintain their sustained fast growth. Among those radiotracers,
18

F-labeled AMT has shown high tumor uptake and great ability to differentiate

tumor tissue from inflammatory sites in brain tumors and squamous cell
carcinoma[130].

18

F-AMT enters the tumor cells via LAT, which is the only system

that can transport large neutral amino acids with aromatic rings[117]. LAT,
especially its subtype LAT1, was reported to be highly expressed in many cancer
cell lines and positively correlates with tumor growth[118, 135]. So far,

18

F-AMT is

the most suitable amino acid transporter-targeting radiotracer for tumor imaging,
regardless of low synthesis yield and requirement of an on-site cyclotron to produce
18

F.
Although PET has emerged as an advanced imaging tool for cancer diagnosis,

only a limited number of facilities around the world can afford complete operation of
PET and cyclotron for the local production of short-lived positron-emitting
radionuclides such as 11C and

18

F. Therefore, mature technologies, i.e. SPECT and

its combination with CT, still play important and irreplaceable roles in nuclear
106

imaging area[15]. The most common radionuclide for SPECT is

99m

Tc ( t1/2=6.02 h),

which is produced by an in-house generator and does not require the cyclotron[14].
Due to their similar chemistry, the diagnostic radioisotope
radioisotope

99m

Tc and the therapeutic

188

Re could be labeled to the same ligand, which leads to the

diagnostic/therapeutic matched pair. Unlike most of the cyclotron-produced
radionuclides that utilize the covalent chemistry for labeling,

99m

Tc requires a

“chelator” to conjugate the radionuclide with the target ligand. The nitrogen, oxygen
and sulfur combination have been shown to be stable chelators for 99mTc such as N4
(e.g.

DOTA,

cyclam-14),

N3S

(e.g.

mercaptoacetyltriglycine),

N2S2 (e.g.

ethylenedicysteine diethyl ester), NS3, S4 (e.g. sulfur colloid), DTPA, O2S2 (e.g.
dimercaptosuccinic acid), and HYNIC[68, 101-105].
Here,

we

report

the

synthesis

of

precursor

O-[3-(1,4,8,11-

tetraazacyclotetradecan)-propyl]-α-methyl tyrosine (N4-AMT) and its radiolabeling
with 99mTc. In vitro cellular uptake kinetics and planar scintigraphic imaging of

99m

Tc-

N4-AMT were also evaluated in breast cancer models.

II.

Materials and methods

Chemicals and Analysis
All chemicals and sources used here were previously described in Chapter 2.

Synthesis of Precursor N4-AMT
a)

α-Methyl tyrosine ethylester (Compound 2)
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Thionyl chloride (10 mL; 137.42 mmol) was added to a solution of αmethyltyrosine 1 (10.00 g; 51.22 mmol) in anhydrous ethanol (60 mL) at 0 0C, and
then heated at 78 0C for 4 h while stirring. After cooling, the volume of the reaction
mixture was reduced to 20 mL, and then 10 mL of triethylamine was added into it.
The mixture was poured into 100 mL of water and extracted with chloroform. The
combined organic layers were dried over MgSO4. The desired compound was
obtained as white solid. Yield: 9.00 g (40.32 mmol, 78.75 %). 1H-NMR (CDCl3) δ =
7.02 (d, 2H, J = 8.4 Hz), 6.70 (d, 2H, J = 8.4 Hz), 4.22 (dd, 2H, J = 7.2 Hz, J = 7.8
Hz), 3.14 (dd, 2H, J = 13.5 Hz, J = 13.5), 1.42 (s, 3H), 1.33 (t, 3H, J = 16.2 Hz) ppm.
13

C-NMR δ = 175.47, 156.36, 130.66, 126.39, 114.87, 61.05, 58.65, 45.29, 24.08,

13.07 ppm, MS: m/z = 224.23 [M]+.

b)

N-t-Butoxycarbonyl-α
α-methyl tyrosine ethylester (Compound 3)
Compound 2 (2.09 g; 9.36 mmol) was dissolved in 40 mL of anhydrous DMF

under nitrogen, and treated with triethylamine (2.78 mL; 20 mmol) while stirring.
Ditertiarbutyl dicarbonate (3.27g; 15 mmol) was added to the reaction mixture and
stirred over night at room temperature. The solvent was removed under reduced
pressure to yield a residue, which was extracted with ethyl acetate and dried with
anhydrous MgSO4. The extraction was filtered and evaporated to dryness to give
yellow oil which was purified by loading on to a silica gel-packed column and eluted
with hexane: ethyl acetate (5: 1.5 v/v). After evaporation of the solvent, yellow oil 3
was obtained. Yield: 2.00 g (6.18 mmol, 66.20 %). 1H-NMR (CDCl3) δ = 6.97 (d, 2H,
J = 8.4 Hz), 6.75 (d, 2H, J = 8.7 Hz), 4.22 (dd, 2H, J = 2.7 Hz, J = 7.2 Hz), 3.32 (dd,
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2H, J = 15.0 Hz, J = 13.5), 1.55 (s, 3H), 1.48 (s, 9H), 1.32 (t, 3H, J = 18.0 Hz) ppm.
13

C-NMR δ = 174.16, 155.04, 154.51, 131.16, 128.50, 115.14, 77.25, 61.64, 60.54,

40.99, 28.39, 23.55, 14.77 ppm, MS: m/z = 324.36 [M]+.

c)

N-t-Butoxycarbonyl-O-[3-hydroxypropyl]-α
α-methyl tyrosine ethylester

(Compound 4)
Sodium metal (0.09 g; 14.02 mmol) was dissolved in 30 mL of anhydrous
ethanol with stirring under nitrogen. Compound 3 (1.00 g; 3.09 mmol) was dissolved
in 50 mL of anhydrous ethanol and treated with sodium ethoxide solution, and
refluxed for 2.5 h at 70 0C. 3-Bromopropanol (0.56 mL; 6.18 mmol) was added into
the reaction mixture, which was heated continuously over night. The ethanol was
removed under reduced pressure and replaced with 40 mL of ethyl acetate. The
solution was then washed with water and dried over MgSO4. After removal of the
solvent, the crude compound was purified by a silica gel-packed column and eluted
with hexane/ ethylacetate (2/1), giving 0.83 g (2.17 mmol, 71 % yield) of the product
as clear yellow oil.

1

H-NMR (CDCl3) δ = 7.01 (d, 2H, J = 6.3 Hz), 6.81 (d, 2H, J =

6.6 Hz), 4.20 (dd, 2H, J = 5.1 Hz, J = 5.1 Hz), 4.12 (t, 2H, J = 15.0 Hz), 3.86 (t, 2H,
J = 10.2 Hz), 3.16 (dd , J = 13.5 Hz, J = 12.9 Hz), 2.06 (m, 2H), 1.54 (s, 3H), 1.47 (s,
9H), 1.31 (t, 3H, J = 12.3 Hz) ppm.

13

C-NMR δ = 174.01, 171.91, 157.73, 154.35,

131.07, 128.65, 114.14, 79.39, 65.65, 61.54, 60.40, 60.24, 40.79, 32.01, 28.39,
23.58, 14.15 ppm, MS: m/z = 381.033 [M] +.
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d)

N-t-Butoxycarbonyl-O-[3-Br-propyl]-α
α-methyl tyrosine ethylester

(Compound 5)
A solution of 4 (5.44 g; 16.82 mmol) and 1,3- dibromopropane (136.74 g;
677.30 mmol) in 100 mL acetone was purged with nitrogen for 15 min. Potassium
carbonate (22.62 g; 163.69 mmol) was added to the reaction mixture, the mixture
was then refluxed for 12 h at 75 0C. After the removal of solvents and excessive
reagents under reduced pressure, the residue was dissolved in chloroform, washed
with water and dried over anhydrous magnesium sulfate. After filtration and solvent
evaporation, yellow liquid was purified by a silica gel-packed flash column and
eluted with hexane/ ethylacetate (2/1) to furnish compound 5 as pale yellow liquid.
Yield: 4.80 g (7.52 mmol, 64.69 %). MS: m/z = 446.3 [M] +.

e)

N1, N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane (N1,N4-cyclooxamide)

(Compound 6)
N4 cyclam (15.00 g; 74.88 mmol) was dissolved in 150 mL of anhydrous
ethanol, and then diethyl oxalate (10.94 g; 74.88 mmol) was added. The reaction
mixture was refluxed 18 h at 75 0C. The solvent was evaporated and the crude
product was recrystallized in acetone : ethanol to yield white crystals of N1,N4dioxylyl-1,4,8,11-1,5,8,12-tetraazabicyclotetradecane (N1,N4-cyclooxamide) 6 . Yield:
13.64 g (17.31 mmol, 72.00 %). MS: m/z = 255.33 [M]+.
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f)

N-t-Butoxycarbonyl-O-[3-( N1,N4-dioxylyl-1,4,8,11-

tetraazabicyclotetradecane)-propyl]-α
α-methyl tyrosine ethylester (Compound
7)
Compound 6 (1.00 g; 3.93 mmol) was dissolved in 20 mL of anhydrous DMF
and treated with a solution of N-t-Butoxycarbonyl-O-[3-Br-propyl]-α-methyl tyrosine
ethylester 5 (1.74 g; 3.93 mmol) in 40 mL of DMF under nitrogen atmosphere. The
reaction mixture was heated to reflux for 18 h at 75 0C, and then allowed to cool
down to room temperature. The solvent was removed in vacuo. The residue was
dissolved in chloroform (30 mL), washed with water and 1M Na2CO3, (12 mL), and
then separated for the organic layer. The organic layer was dried with anhydrous
Magnesium sulfate, filtered and evaporated. The crude compound was purified by a
silica gel-packed column and eluted with chloroform/ methanol (9/1). Yield: 1.00 g
(1.63 mmol, 42.00 %). MS: m/z = 618.38 [M]+.

g)

O-[3-(N1,N4-dioxylyl-1,4,8,11-tetraazabicyclotetradecane)-propyl]-α
α-

methyltyrosine ethylester (Compound 8)
Compound 7 (0.25 g; 0.40 mmol) was dissolved in dichloromethane (10 mL),
and then trifloroacetic acid (1.0 mL) was added to it. The solution was stirred over
night at room temperature, and volatiles were removed in vacuo. The crude
compound was purified by chromatography over silica gel (chloroform: methanol 9:1)
as white solid. Yield: 0.20 g (0.39 mmol; 95.69 %). MS: m/z = 517.63 [M]+.
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h)

O-[3-(1,4,8,11-tetraazabicyclohexadecane)-propyl]-α-methyl tyrosine (N4-

AMT) (Compound 9)
10N NaOH (2 mL) was added to a solution of compound 8 (0.20 g; 0.39 mmol),
which was dissolved in 5 mL of water. The reaction mixture was stirred and refluxed
over night at 90 0C. The solvent was evaporated under vacuum, giving white solid,
which was dissolved in 5 mL of water and neutralized with 5N HCl solution to pH =
7. It was lyophilized and obtained as white solid. The solid was stirred in 25 mL
anhydrous methanol. After filtration and solvent evaporation, white solid was
obtained. Yield: 0.20 g (0.46 mmol: 99.0 %). MS: m/z = 436.327 [M]+.

Radiolabeling of N4-AMT with 99mTc
N4-AMT (1 mg) was dissolved in 0.2 mL sterile water, followed by adding tin (II)
chloride (0.1 mL, 1 mg/mL). Required amount of Na99mTcO4 was added to N4-AMT
solution. Radiochemical purity was determined by radio-HPLC (Waters, Milford, MA),
eluted with acetonitrile: water (7:3) using a flow rate of 0.5 mL/min.

Determination of the Partition Coefficient
To determine the lipophilicity, 20 µL of

99m

Tc-N4-AMT was added into an equal

volume mixture of 1-octanol and sterile water in a centrifuge tube. The mixture was
vortexed at room temperature for 1 min and then centrifuged at 5000 rpm for 5 min.
From each phase, 0.1 mL of the aliquot was taken out and the radioactivity was
measured by gamma counter (Cobra Quantum; Packard, MN). The measurement
was repeated for three times, and care was taken to avoid cross contamination
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between the phases. The partition coefficient value, expressed as logP, was
calculated using the following equation:
LogP = Log (radioactivity in 1-octanol layer / radioactivity in sterile water layer)

In Vitro Cellular Uptake Studies
Rat breast tumor cell line 13762 (American Type Culture Collection, Rockville,
MD) was selected and the same cell line was used to create the animal model for in
vivo evaluation. Cells were maintained in Dulbecco’s modified Eagle’s medium and
nutrient mixture F-12 Ham (DMEM/F12; GIBCO, Grand Island, NY) at 37 oC in a
humidified atmosphere containing 5% CO2. Cells were plated onto 6-well tissue
culture plates (2x105 cells/well) and incubated with
uCi/well),

99m

Tc-N4 (0.025 mg/well, 8 uCi/well) or

99m

Tc-N4-AMT (0.05 mg/well, 8

18

F-FDG (8 uCi/well) for 0-4 h.

After incubation, cells were washed with ice-cold PBS twice and detached by
treating them with 0.5 mL of trypsin for 5 min. Cells were then collected and the
radioactivity was measured with gamma counter (Cobra Quantum; Packard, MN).
Data were expressed in mean ±S.D. percent of cellular uptake (%Uptake) in
triplicate.

In Vitro Competitive Inhibition Study
To investigate the transport mechanisms of

99m

Tc-N4-AMT, the competitive

inhibition study using L-tyrosine was conducted. The 13762 rat breast tumor cells
were co-incubated with

99m

Tc-N4-AMT (8 µg/well, 8 µCi/well) and L-tyrosine for up

to 1 h. A set of concentrations of L-tyrosine (10-1000x of the N4-AMT concentration)
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were used. After incubation, cells were washed with ice-cold PBS twice and
detached by treating them with 0.5 mL of trypsin for 5 min. Cells were then collected
and the radioactivity was measured by gamma counter. Data were expressed in
mean ±S.D. percent of cellular uptake (%Uptake) in triplicate.

Blood Clearance
All animal work was carried out in the Small Animal Imaging Facility (SAIF) at
UTMDACC under a protocol approved by Institutional Animal Care and Use
Committee (IACUC). For blood clearance analysis, three normal female Fischer 344
rats (150±25 g) (Harlan Sprague-Dawley, Indianapolis, IN) were intravenously
injected with 30 µCi

99m

Tc-N4-AMT. Blood samples were drawn through lateral tail

vein at several time-points from 5 min to 24 h (n=3/rat) by microliter pipettes (10 µL).
The blood samples were measured for radioactivity by gamma counter, and then
were calculated as percentage of the injected dose per gram of blood (%ID/g).

In vivo Tissue Distribution Studies
Tissue distribution studies of

99m

Tc-N4-AMT (study I, n=9) and

18

F-FDG (study

II, n=9) were conducted by using normal female Fischer 344 rats (150±25 g, n=18).
For each compound, the rats were divided into three groups for three time intervals
(0.5, 2, 4 h for 99mTc-N4-AMT; 0.5, 1, 2 h for 18F-FDG; n=3/time point). The injection
activity was 25±0.5 µCi/rat intravenously. At each time interval, the rats were
sacrificed, and the selected tissues were excised, weighed and measured for
radioactivity by gamma counter. Each sample was calculated as percentage of the
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injected dose per gram of tissue wet weight (%ID/g). Counts from a diluted sample
of the original injection were used as reference.

Planar Scintigraphic Imaging Study
Female Fischer 344 rats were inoculated subcutaneously with 0.1 mL of breast
5

tumor cells 13762 suspension in PBS (10 cells/rat) into the right legs. Planar
scintigraphic imaging of

99m

Tc-N4-AMT was performed 12-14 days after inoculation

when tumors reached approximately 1 cm in diameter. Planar scintigraphic images
were obtained using M-CAM (Siemens Medical Solutions, Hoffman Estates, IL)
equipped with a Low Energy High Resolution collimator. Anesthetized breast tumorbearing rats were injected intravenously with

99m

Tc-N4-AMT (0.3 mg/rat, 300 µCi/rat;

n=3). The images were acquired up to 4 h post-administration of tracers. Computer
outlined regions of interest (ROIs in counts per pixel) between tumor and muscle
were used to calculate tumor/muscle (T/M) ratios. Percentage of the injected dose
(%ID) of tumor was also calculated from the reference standard, which was 1/10 of
the original injection activity.

In Vivo Uptake Blocking Study
To ascertain whether

99m

Tc-N4-AMT uptake is mediated specifically by LAT, in

vivo blocking studies using the unlabeled L-Tyrosine as the competitive inhibitor
was conducted. The same animal model used in the planar scintigraphic imaging
study was employed. Unlabeled L-Tyrosine (50 mg/kg) dissolved in 0.3 mL saline
(pH adjusted to 2-3) was administered intravenously to mammary tumor–bearing
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rats 1 h prior to

99m

Tc-N4-AMT injection. Planar scintigraphic images were acquired

up to 4 h, and ROIs of liver, kidneys, tumor, and muscle were used to calculate the
ratios

of

liver/muscle,

kidney/muscle,

and

tumor/muscle,

respectively.

In

addition, %IDs of liver, kidneys, tumor, and muscle were calculated from the
reference standard, which was 1/10 of the original injection activity. The results
were compared with those from the rats injected with 99mTc-N4-AMT alone (control).

Tumor and Inflammation Uptake Comparison In Vivo
To investigate whether

99m

Tc-N4-AMT can differentiate tumor from the

inflammatory tissue, a rat model bearing both mammary tumor and turpentine oilinduced inflammation was created. 13762 rat mammary tumor cells (105 cells/0.1
mL PBS/rat) were inoculated into the right calf muscles of the female Fischer 344
rats. After the tumors reached to 1 cm in diameter, turpentine oil (0.1 mL/rat) was
injected into the left calf muscles of the rats to induce inflammation. The
anesthetized rats (n=3) were injected intravenously with

99m

Tc-N4-AMT 24 h after

the turpentine injection. Planar scintigraphic images were acquired up to 4 h, and
ROIs of tumor, inflammation, and muscle were used to calculate the tumor-tomuscle

ratios

(T/Ms),

inflammation-to-muscle

ratios

(I/Ms),

and

tumor-to-

inflammation ratios (T/Is), respectively. Same animal model was used to evaluate
18

F-FDG. Micro-PET imaging of

18

F-FDG was performed using R4 micro-PET

scanner (Concorde Microsystems, TN). The rats were injected intravenously with
18

F-FDG (500 uCi/rat, n=3), and dynamic PET scans were obtained for 90 min with

a spatial resolution of 2.2 mm. PET images were reconstructed by using the
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ordered subset expectation maximization (OSEM) algorithm. T/Ms, I/Ms and T/Is
ratios were calculated based on the regional radioactivity concentrations (µCi/cm3)
that were estimated from the average pixels within ROIs drawn around the tumor,
inflammation or muscle on transverse slices of the reconstructed image sets.

III.

Results

Chemistry and Radiochemistry
Precursor N4-AMT was synthesized via an eight-step procedure and the total
synthesis yield was 14%. The synthetic scheme is shown in Fig.5.1. The structure
and purity of N4-AMT was confirmed by 1H- and
HPLC. For N4-AMT, the 1H- and

13

C- NMR, mass spectra, and

13

C-NMR results were 1H NMR (D2O) δ = 7.21 (d,

2H, J = 9.00 Hz), 7.00 (d, 2H, J = 9.00 Hz), 4.14 (t, 2H, J = 12.0 Hz), 3.10 (m, 5H),
2.94 (m, 2H), 2.84 (m, 13H), 1.95 (m, 6H), 1.33 (s, 3H) ppm.13C NMR δ = 180.69,
163.42, 163.16, 162.88, 162.60, , 157.06, 131.40, 129.19, 117.57, 115.26, 115.10,
112.93, 66.25,60.73, 53.69, 51.46, 49.88, 49.26, 48.04, 47.84, 46.60, 45.42, 45.07,
43.94, 24.71, 24.32, 23.62, 22.55 ppm.
Precursor N4-AMT was labeled with

99m

Tc successfully in a high radiochemical

purity (>96%). For HPLC, the retention time of
logP of 99mTc-N4-AMT was -1.42±0.169.
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99m

Tc-N4-AMT was 6.899 min. The

Figure 5.1. Synthetic scheme of manufacturing of the precursor N4-AMT.
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In Vitro Cellular Uptake Studies
The cellular uptake kinetics of

99m

Tc-N4-AMT,

99m

Tc-N4, and

18

F-FDG in rat

breast tumor cells is shown in Fig. 5.2. There was a drastically increased uptake for
99m

Tc-N4-AMT at 15-240 min, but not for

that

99m

99m

Tc-N4 chelator itself, which suggested

Tc-N4-AMT can enter and accumulate into tumor cells rapidly and

specifically. In addition, the %Uptake of

99m

Tc-N4-AMT was much higher than that

of 18F-FDG.
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Figure 5.2. Time course of 99mTc-N4-AMT, 99mTc-N4 and 18F-FDG uptake in rat breast
tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D. percentage of
cellular uptake (%Uptake).
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Competitive Inhibition Study of 99mTc-N4-AMT
After incubated with L-tyrosine at 10-1000 times as high as the concentrations
of N4-AMT, 13762 cells showed a significant decrease in

99m

Tc-N4-AMT uptake

only at the 150- and 200-time concentrations (Fig. 5.3). These results indicate that
99m

Tc-N4-AMT and L-tyrosine may be transported via the same transporter system

LAT; however, LAT may not be the only transport route for 99mTc-N4-AMT.
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Figure 5.3. Competitive inhibition uptake of 99mTc-N4-AMT by L-tyrosine in rat breast
tumor cell line 13762 up to 1 h. A set of concentrations of L-tyrosine [150X and 200X
of N4-AMT concentration (8 mg/well)] were used. Data are expressed in mean ± S.D.
percentage of cellular uptake (%Uptake).
*P<0.05 compared with the control group.
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Blood Clearance
The blood clearance curve for

99m

Tc-N4-AMT in normal Fischer 344 rats (n=3)

is shown in Fig. 5.4. The plasma half-life of the distribution phase (t1/2 α) was
10.71±0.794 min, while that of the elimination phase (t1/2 β) was 99.32±5.182 min.
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Figure 5.4. Blood clearance (%ID/g) of 99mTc-N4-AMT in normal female Fischer 344
rats (n=3). The data represent the mean radioactivity expressed as a percentage of
the injected dose per gram of blood ± S.D.
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In Vivo Tissue Distribution Studies
The tissue distribution results of

99m

Tc-N4-AMT and

18

F-FDG in the normal

Fischer 344 rats are shown in Tables 5.1 and 5.2, respectively. Low thyroid and
stomach uptake of

99m

Tc-N4-AMT was observed, suggesting its high in vivo stability.

Table 5.1. Biodistribution of 99mTc-N4-AMT in normal Fischer 344 female rats.

%ID/g

30 MIN

120 MIN

240 MIN

blood

0.74 ±0.024

0.28 ±0.010

0.18 ±0.008

heart

0.18 ±0.013

0.08 ±0.006

0.05 ±0.003

lung

0.44 ±0.029

0.22 ±0.004

0.13 ±0.008

thyroid

0.57 ±0.040

0.31 ±0.015

0.24 ±0.012

pancreas

0.18 ±0.006

0.09 ±0.005

0.06 ±0.002

liver

1.40 ±0.077

0.83 ±0.045

0.60 ±0.023

spleen

0.24 ±0.004

0.19 ±0.002

0.18 ±0.011

kidney

5.77 ±0.355

5.32 ±0.180

4.74 ±0.332

stomach

0.50 ±0.029

0.42 ±0.031

0.43 ±0.026

intestine

0.33 ±0.019

0.18 ±0.010

0.13 ±0.006

muscle

0.09 ±0.007

0.03 ±0.002

0.02 ±0.001

bone & joint

0.27 ±0.061

0.11 ±0.006

0.06 ±0.003

brain

0.03 ±0.005

0.01 ±0.001

0.01 ±0.000

Each rat received 99mTc-N4-AMT (25 µCi, intravenously). Each value is percent of injected
dose per gram weight (n= 3)/time interval. Each data represents mean of three
measurements with standard deviation.
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Table 5.2. Biodistribution of 18F-FDG in normal Fischer 344 female rats.

%ID/g

30 MIN

60 MIN

blood

0.40 ±0.042

0.13 ±0.006

0.06 ±0.002

heart

1.57 ±0.056

1.38 ±0.126

1.08 ±0.068

lung

0.55 ±0.056

0.42 ±0.024

0.46 ±0.027

thyroid

1.07 ±0.080

1.04 ±0.040

1.05 ±0.069

pancreas

0.26 ±0.028

0.21 ±0.006

0.20 ±0.016

liver

0.40 ±0.048

0.16 ±0.006

0.13 ±0.012

spleen

0.82 ±0.081

0.74 ±0.032

0.86 ±0.071

kidney

0.71 ±0.051

0.37 ±0.012

0.24 ±0.018

stomach

0.61 ±0.078

0.44 ±0.031

0.39 ±0.030

intestine

0.69 ±0.068

0.53 ±0.035

0.52 ±0.025

muscle

0.33 ±0.040

0.34 ±0.027

0.74 ±0.024

bone& joint

0.33 ±0.036

0.44 ±0.065

0.50 ±0.034

brain

2.00 ±0.149

1.99 ±0.046

1.39 ±0.086

Each rat received

120 MIN

18

F-FDG (25 µCi, intravenously). Each value is percent of injected dose

per gram weight (n =3)/time interval. Each data represents mean of three measurements
with standard deviation.
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Planar Scintigraphic Imaging Study
The representative planar scintigraphic images of 99mTc-N4-AMT at 30 min, 2h,
and 4 h in breast tumor-bearing rats are shown in Fig. 5.5. Tumors were clearly
detected by

99m

Tc-N4-AMT at all time-points. The T/M ratios at 30 min, 2h, and 4 h

were 5.02, 4.04, and 5.00, respectively. Tumor %IDs at these three time-points
were 0.76%, 0.51%, and 0.48%, respectively (Fig. 5.5).

30 MIN

120 MIN

240 MIN

T

T/M = 5.02
Tumor %ID: 0.76

T/M = 4.04
Tumor %ID: 0.51

T/M = 5.00
Tumor %ID: 0.48

Figure 5.5. Planar scintigraphy of 99mTc-N4-AMT at 30 – 240 min in rat breast tumorbearing rats (T: tumor).
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In Vivo Uptake Blocking Study
The liver, kidneys, tumor, and muscle %IDs of

99m

Tc-N4-AMT, as well as the

ratios of these organs to muscle before and after in vivo blocking by unlabeled LTyrosine were listed in Table 5.3 and 5.4. By using the blocking agent L-Tyrosine,
99m

Tc-N4-AMT uptake in liver, kidney, and tumor decreased significantly at all time-

points. Muscle uptake also decreased at the 30 min time-point, which may due to
the blood flow effect. These results suggest that

99m

Tc-N4-AMT utilizes the same

transport system LAT as L-Tyrosine does in vivo.

Table 5.3. Percentage of injected dose (%ID) of selected organs before and after in vivo
blocking of

99m

Tc-N4-AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red

font indicates the decreased %ID when compared to the corresponding control group.
Blue shading indicates P<0.05 when compared to the corresponding control group
(n=3/group/time interval).
30 min

2 hr

4hr

%ID
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver

7.63±0.47

6.31±0.18

17.30%

5.12±0.24

4.40±0.33

14.06%

4.49±0.32

3.39±0.09

24.50%

Kidney

5.81±0.35

4.62±0.45

20.48%

4.26±0.25

3.32±0.14

22.07%

4.35±0.33

3.05±0.16

29.89%

Tumor

2.71±0.22

1.63±0.05

39.85%

0.84±0.05

0.43±0.04

48.81%

0.55±0.04

0.37±0.02

32.73%

Muscle

0.58±0.11

0.42±0.04

27.59%

0.11±0.02

0.11±0.04

0.00%

0.077±0.005

0.082±0.012

-6.49%
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Table 5.4. Selected organ to muscle ratios before and after in vivo blocking of

99m

Tc-N4-

AMT by unlabeled L-Tyrosine in mammary tumor-bearing rats. Red font indicates the
decreased %ID when compared to the corresponding control group. Blue shading
indicates P<0.05 when compared to the corresponding control group (n=3/group/time
interval).
30 min

2 hr

4hr

Ratio
Control

Block

Decrease

Control

Block

Decrease

Control

Block

Decrease

Liver/Muscle

13.1±0.5

15.1±0.4

-15.27%

45.6±1.5

41.1±2.1

9.87%

58.0±2.3

41.1±2.2

29.14%

Kidney/Muscle

9.96±0.49

11.0±0.53

-10.24%

38.0±1.3

31.1±2.4

18.16%

56.1±1.3

37.0±0.3

34.05%

Tumor/Muscle

4.65±0.28

3.89±0.1

16.34%

7.48±0.34

4.03±0.16

46.12%

7.12±0.35

4.55±0.27

36.10%
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Tumor and Inflammation Uptake Comparison In Vivo
The representative planar scintigraphic images of
the micro-PET images of

99m

Tc-N4-AMT, as well as

18

F-FDG in breast tumor and inflammation-bearing rats

are shown in Fig. 5.6 and Fig. 5.7, respectively. The T/M of

99m

Tc-N4-AMT at each

time-point was much higher than I/M. Although T/I at all time-points were above 1,
which indicated that tumor had higher uptake than the inflammation site, the ratios
were similar to those of

18

F-FDG. Therefore, these results suggested that

99m

Tc-N4-

AMT was not superior to 18F-FDG in differentiating tumor from inflammation.

30 MIN

120 MIN

240 MIN

I
T

T/M
I/M
T/I

30 min

2 hr

4 hr

4.49
2.95
1.52

5.59
3.47
1.61

5.15
2.71
1.90

Figure 5.6. Planar scintigraphic images of 99mTc-N4-AMT at 30 – 240 min in rat breast
tumor and inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle
ratios (T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios
(T/Is) are listed below the figure.
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Transverse

T

Saggital

Axial

I
T

T

I

I

30 min

60 min

90 min

T/M
I/M
T/I

30 min

60 min

90 min

5.88

7.54

4.90

3.43

3.77

2.72

1.71

1.99

1.80

Figure 5.7. microPET images of 18F-FDG at 30 – 90 min in rat breast tumor and
inflammation-bearing rats (T: tumor, I: inflammation). The tumor-to-muscle ratios
(T/Ms), inflammation-to-muscle ratios (I/Ms), and tumor-to-inflammation ratios (T/Is)
are listed below the figure.
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IV.

Discussion
The present study investigated the imaging capability of

99m

Tc-N4-AMT in

breast tumor models in vitro and in vivo. For chemical synthesis, the precursor N4AMT was synthesized via an eight-step procedure (Fig. 5.1). Commercially
available α-methyl tyrosine 1 was converted into corresponding acid chloride, then
to ethyl ester by reacting with thionyl chloride in ethanol. The amine in α-methyl
tyrosine ethyl ester 2 was protected as its Boc-derivative N-t-butoxycarbonyl-αmethyl tyrosine ethylester 3 with triethylamine and di-t-butyldicarbonate in DMF.
The chain at the -OH group was extended when compound 3 was treated with 1, 3dibromopropane and obtained as N-t-butoxycarbonyl-O-[3-bromopropyl]-α-methyl
tyrosine ethylester 4. Acylation of 1,4,8,11- tetraazacyclo-tetradecane (N4 cyclam)
with diethyloxalate led to N1,N4-dioxalyl 1,4,8,11- tetraazacyclotetradecane (N1,N4cyclamoxamide) 5. Under SN2 condition 4 and 5 were efficiently converted to
alkylated

compound

N-t-butoxycarbonyl-O-[3-(N1,N4-dioxalyl-1,4,8,11-

tetraazacyclotetradecane)-propyl]-α-methyl tyrosine ethylester 6. Exposure of 6 to
trifloroacetic acid in CH2Cl2 caused qualitative de-t-butoxycarboxylation to yield O[3-(N1,

N4-dioxalyl

1,4,8,11-tetraazacyclotetradecane)-propyl]-α-methyl

tyrosine

ethylester 7. 10 N NaOH in water at 75 0C promoted the hydrolysis of ester to acid
and a simultaneous deoxalation of 7 to yield the final compound O-[3-(1,4,8,11tetraazacyclotetradecan)-propyl]-α-methyl tyrosine (N4-AMT) 8. The total synthesis
yield was 14%, which can be adapted to industrial manufacturing. The structure and
purity of the compounds at each step were validated by 1H- and 13C- NMR, mass
spectra, and HPLC. Precursor N4-AMT could be labeled with
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99m

Tc successfully in

a high radiochemical purity (>96%). Given that

99m

Tc-N4-AMT is a kit-product and

labeled without any further purification, the radiochemical yield was assumed to be
identical to its radiochemical purity.
In cellular uptake study,

99m

tumor cells, and the %Uptake of
the chelator
99m

99m

Tc-N4-AMT was taken up rapidly by rat mammary
99m

Tc-N4-AMT was significantly higher than that of

Tc-N4, suggesting its high specificity in tumor uptake. Besides,

Tc-N4-AMT has much more uptake than

model. In competitive inhibition study,

99m

18

F-FDG in this in vitro breast cancer

Tc-N4-AMT uptake could be significantly

inhibited by L-tyrosine only at the 150- and 200-time concentrations, which indicates
that

99m

Tc-N4-AMT and L-tyrosine may be transported via the same transporter

system LAT; however, LAT may not be the only transport route for

99m

Tc-N4-AMT.

To further investigate other transport routes, different types of amino acid
transporter inhibitors need to be tested in order to block the

99m

Tc-N4-AMT uptake

in this breast cancer cell line in future.
For in vivo evaluation,

99m

Tc-N4-AMT had a relatively fast blood clearance in

normal Fischer 344 rats (Fig. 5.4). Biodistribution study showed that

99m

Tc-N4-AMT

had a favorable distribution pattern in normal rats (Table 5.1). The two major organs
for

99m

Tc-N4-AMT metabolism are kidneys and liver. In planar imaging studies

shown in Fig. 5.5, tumors were clearly detected by

99m

Tc-N4-AMT at all time-points.

Although its T/Ms were relatively high, the tumor %IDs were lower than that of other
99m

Tc-labeled tyrosine derivatives we developed previously. To ascertain whether

99m

Tc-N4-AMT uptake is mediated specifically by LAT, we then conducted the in

vivo uptake blocking studies using the unlabeled L-Tyrosine as the competitive
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inhibitor (Table 5.3 and 5.4). Upon blocking,

99m

Tc-N4-AMT uptake in liver, kidney,

and tumor decreased significantly at all time-points. Although muscle uptake also
decreased at the 30 min time-point, the decreasing rate was not statistically
significant and it may due to the blood flow effect. These results suggest that

99m

Tc-

N4-AMT may utilize the same transport system LAT as L-Tyrosine does in vivo. To
test whether

99m

Tc-N4-AMT can distinguish tumor from inflammatory tissues, we

have established a rat model bearing both mammary tumor and turpentine oilinduced inflammation. Although T/Is at all time-points were above 1, which indicated
that tumor had higher uptake than the inflammation site, the ratios were similar to
those of

18

F-FDG. Nevertheless, since the uptake in inflammatory tissue was

caused by blood flow effect, T/I ratios of
Therefore,

99m

99m

Tc-N4-AMT increased by time.

Tc-N4-AMT may be able to distinguish tumor from inflammation in a

later time-point by taking the advantage of using the long half-life radioisotope 99mTc.
In addition, we may need to test

99m

Tc-N4-AMT in another animal model using

radiation to induce inflammation in future so it can more similarly mimic the patients
undergoing radiation therapy.
In conclusion, efficient synthesis of N4-AMT was achieved. In vitro cellular
uptake and in vivo imaging findings collectively suggest that

99m

Tc-N4-AMT is a

potential radiotracer for breast cancer imaging. In compliance with the chelating
capability of N4, N4-AMT could be labeled with positron emitting radionuclides such
as Gallium-68 or with short-ranged beta emitters for internal radiotherapeutic
purposes hereafter.
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CHAPTER 6

99m

Overview: comparison of

Tc-labeled Tyrosine-

based radiotracers in breast cancer imaging
In this dissertation, four

99m

Tc-labeled tyrosine derivatives have been

synthesized and evaluated in vitro and in vivo for their imaging potential in breast
cancer models (Fig. 6.1). The detailed methods and results of the synthesis and
evaluation of each radiotracer have already been stated in Chapter 2-5. The studies
designed for each specific aim were listed in Table 6.1. Here, we will compare these
four radiotracers and score them as 1 to 4. Score 1 indicates the best compound
and score 4 is the worst compound for each study. Therefore, the compound with
the least score will be the best radiotracer for imaging breast cancer modeled here
overall.

O

O

H2N

H2N

OH

OH

H3C
O
NH N

O
HO
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OH

O
HO
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EC-AMT
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SH HS

NH

NH N

N
H
N

H2N
O

NH
H
N

O

N
H
N

H2N
O

CH3 OH

N4-Tyrosine

N4-AMT

Figure 6.1. Proposed structures of four tyrosine-based precursors.
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Table 6.1. The studies designed to synthesize and evaluate four radiotracers.
EC-AMT
Precursor Synthesis

SA1

99m Tc

Labeling

Partition Coefficient
Uptake Kinetics

SA2
Competitive Inhibition using L-Tyrosine
Blood Clearance
Biodistribution

SA3

Planar Imaging (breast cancer model)
Planar Imaging (in vivo blocking)
Planar Imaging (breast cancer vs. inflammation model)
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EC-Tyrosine

N4-AMT

N4-Tyrosine

I.

Specific Aim 1
Table 6.2 summarized the chemical synthesis of four precursors. Since N-t-

Butoxycarbonyl-L-tyrosine methyl ester, the starting material of the protected Brtyrosine compound was commercially available; the required synthetic steps of ECTyrosine and N4-Tyrosine were fewer than those of their α-methyl derivatives,
hence, the overall synthetic yields were much higher than EC-AMT and N4-AMT,
respectively. As shown in Table 6.2, the best compound with fewest synthesis steps
and highest synthetic yield was EC-Tyrosine. Nevertheless, the other three
compounds also had acceptable synthetic yield.
When label the precursors with

99m

Tc, the radiochemical purity of four

compounds was all above 95%. Since they are kit-products and labeled without any
further purification, the radiochemical yield is assumed to be identical to their
radiochemical purity. However, EC seemed to have better chelation ability with
99m

Tc than N4 because EC-AMT and EC-Tyrosine can be labeled with

lesser physical amount than their N4 counterpart.
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99m

Tc using

Table 6.2. Summary of the chemical synthesis of four precursors.

Synthesis Steps

Overall Yield

EC-AMT

5

23%

EC-Tyrosine

3

80%

N4-AMT

8

14%

N4-Tyrosine

5

38%

The partition coefficient values (logPs) of four radiotracers were listed in Table
6.3. Since all four compounds are small molecule, the compound with higher
lipophilicity is preferred because they will have better chance to be slowly washed
out from body than the compound with lower lipophillicity. Based on the results,
99m

Tc-EC-AMT had highest lipophilicity and therefore was the best compound

among these four radiotracers. As expected, the logPs of tyrosine-based
radiotracers were lower than those of their α-methyl derivatives. As we know, the
lower logP indicates the lower lipophilicity of the compound. The result verified our
hypothesis that the lipophilicity of tyrosine-based radiotracer could be increased by
adding a methyl group on its α-carbon. In addition, we found that EC-chelated
radiotracers had higher lipophilicity than their N4 counterpart. When we compared
lipophilicity of chelator EC and N4 using ChemBioDraw Ultra 12.0 software
(CambridgeSoft Corporation, Cambridge, MA), the same result was presented. The
logP of precursor EC was -1.05 whereas that of N4 was -1.3. Although it contains
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two hydrophilic carboxylic groups, the higher logP of EC may be due to its two
lipophilic thiol groups.

Table 6.3. The partition coefficient value (logP) of four radiotracers at pH=5-6 (n=6).

LogP

99mTc-EC-AMT

99mTc-EC-Tyrosine

99mTc-N4-AMT

99mTc-N4-Tyrosine

-1.14±0.072

-2.02±0.168

-1.42±0.169

-2.83±0.082

Table 6.4 summarizes the conclusion for Specific Aim 1. From the chemical
point of view, EC-chelated compounds tied for the first place, which suggests that
both EC-chelated compounds have more favorable chemical characteristics than
N4-chelated compounds.

Table 6.4. Conclusion of Specific Aim 1. Score 1 indicates the best compound, and score
4 indicates the worst compound.

EC-AMT EC-Tyrosine N4-AMT
SA1

N4-Tyrosine

Precursor Synthesis

3

1

4

2

99mTc

Labeling

1

1

2

2

Partition Coefficient

1

3

2

4

1

1

2

2

Conclusions
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II.

Specific Aim 2
Specific Aim 2 was to investigate the uptake kinetics and transport

mechanisms of

99m

Tc-labeled tyrosine/AMT-based radiotracer in rat mammary

tumor cell line 13762. This is a well-documented cell line for established in vivo rat
mammary tumor model, as well as for the rat model carrying both tumor and
inflammation employed in differential diagnostic studies. In addition, since we were
evaluating the compounds using planar scintigraphic imaging, rat model would
provide better imaging quality than mouse model in terms of resolution.
Fig. 6.2 demonstrates the cellular uptake kinetics of all four
tyrosine-based compounds in comparison with that of

99m

Tc-labeled

18

F-FDG. All four radiotracers

were taken up rapidly by rat mammary tumor cells and had much higher %Uptake
than that of

18

F-FDG, suggesting their higher imaging potentials than

vitro.
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18

F-FDG in

Figure 6.2. Time course of 99mTc-labeled four radiotracers and 18F-FDG uptake in rat
breast tumor cell line 13762 (0– 240 min). Data are expressed in mean ± S.D.
percentage of cellular uptake (%Uptake).

In competitive inhibition study using the same cell line, the uptake of both
99m

Tc-EC-AMT and 99mTc-EC-Tyrosine could be blocked by L-Tyrosine from 10-time

concentration, whereas that of

99m

Tc-N4-AMT could only be blocked at 150- and

200-time concentrations of precursor. For

99m

Tc-N4-Tyrosine, the uptake could not

be inhibited at any concentration and the uptake even increased by adding
unlabeled L-Tyrosine. Taken together, these findings suggest that

99m

Tc-EC-labeled

compounds most likely share the same transport mechanism as L-Tyrsoine, which
is predominantly transported via LAT system. For

99m

Tc-N4-labeled compounds,

they most likely do not use LAT as a major transport system.
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Table 6.5 summarizes the conclusion for Specific Aim 2. When evaluating
these four compounds in breast cancer cell line,

99m

Tc-EC-AMT shows the most

favorable characteristics in vitro.

Table 6.5. Conclusion of Specific Aim 2. Score 1 indicates the best compound, and score
4 indicates the worst compound.

EC-AMT EC-Tyrosine N4-AMT
SA2

N4-Tyrosine

Uptake Kinetics

1

3

2

4

Competitive Inhibition using L-Tyrosine

1

1

2

3

1

2

2

3

Conclusions
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III.

Specific Aim 3
Specific Aim 3 was to assess the kinetics of

99m

Tc-labeled tyrosine/AMT-based

radiotracer accumulation in tumor and inflammation tissues in mammary tumorbearing rat model. The rat tumor model was created using the same rat mammary
tumor cell line as in the in vitro evaluation.
All four radiotracers had relatively rapid blood clearance in normal Fischer 344
rats (Fig. 6.3). Among them,

99m

Tc-N4-Tyrosine had the fastest clearance for both

distribution phase (T1/2 α=9.31±0.759 min) and excretion phase (T1/2 β=90.14±1.901
min), whereas

99m

Tc-EC-Tyrosine had the slowest but still acceptable clearance for

both distribution phase (T1/2 α=13.68±1.067 min) and excretion phase (T1/2
β=117.51±5.727 min).
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4.500
99mTc-EC-AMT
4.000

99mTc-EC-Tyrosine
99mTc-N4-AMT

3.500

99mTc-N4-Tyrosine
3.000

%ID/g
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2.000
1.500
1.000
0.500
0.000
0
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Time (min)
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Time (min)

99mTc-EC-AMT

99mTc-EC-Tyrosine

99mTc-N4-AMT

99mTc-N4-Tyrosine

T1/2 α

9.41±0.202

13.68±1.067

10.71±0.794

9.31±0.759

T1/2 β

98.75±5.377

117.51±5.727

99.32±5.182

90.14±1.901

Figure 6.3. Blood clearance (%ID/g) of four 99mTc-labeled radiotracers in normal
female Fischer 344 rats up to 240 min (n=3). The data represent the mean
radioactivity expressed as a percentage of the injected dose per gram of blood ± S.D.
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For biodistribution study, all four radiotracers had high in vivo stability in
normal Fischer 344 rats. High kidney uptakes of all compounds were observed up
to 4 hr, indicating that the kidneys are the major organ for metabolism and excretion
of these compounds. The high kidney uptake, nevertheless, could be blocked by
intravenously administration of unlabeled L-Tyrosine, which suggested that the four
radiotracers may utilize the same metabolism and excretion route as L-Tyrosine
does in rat kidneys.
In planar imaging studies, mammary tumors were clearly detected by all
radiotracers up to 4 hr.

99m

Tc-EC-AMT had the highest T/M ratios, and due to the

washout of non-specific uptake, the T/M ratios increased by time. Therefore,

99m

Tc-

EC-AMT is the best compound for imaging mammary tumor in this rat model. The
T/M ratios of the other three compounds also ranged from 4 to 5, and were
promising for tumor imaging, however,

99m

Tc-N4-AMT may have the least potential

because its low tumor %ID.
To ascertain whether the radiotracers uptakes are mediated specifically by
amino acid transporter system LAT, we conducted the in vivo uptake blocking
studies using the unlabeled L-Tyrosine as the competitive inhibitor. Except for
99m

Tc-N4-Tyrosine, all other three compounds were confirmed to transport via the

same LAT system as unlabeled L-Tyrosine does. These findings were consistent
with the in vitro competitive inhibition results. Since the lipophilicity of

99m

Tc-N4-

Tyrosine was much lower in comparison with the other three compounds, it was
possible that N4-Tyrosine was under some conformational changes when be
labeled with

99m

Tc. Thus,

99m

Tc-N4-Tyrosine could not be recognized as an amino

142

acid and then to be transported via LAT system. In order to test this hypothesis, we
need to synthesize the cold reference standard Re-N4-Tyrosine and study its
crystalline structure to confirm the binding site of rhenium in the future.
To test whether the radiotracers could differentiate breast tumor from
inflammation, we performed tumor and inflammation uptake comparison study in
vivo. All radiotracers other than

99m

Tc-EC-AMT had tumor-to-inflammation (T/I) ratio

above 1, which indicated that tumor had higher radiotracer uptake than
inflammatory site. However, when compared with the clinical gold standard 18F-FDG,
only
99m

99m

Tc-EC-Tyrosine had better T/Is up to 4 hr. Therefore, we conclude that

Tc-EC-Tyrosine is the most suitable compound for in differentiating tumor from

inflammatory sites.
Table 6.6 summarizes the conclusion for Specific Aim 3. When evaluating
these four compounds in vivo,
characteristics overall. However,

99m
99m

Tc-EC-AMT shows the most favorable

Tc-EC-Tyrosine will be the most suitable

candidate for differential diagnosis of tumor from inflammation.

Table 6.6. Conclusion of Specific Aim 3. Score 1 indicates the best compound, and score
4 indicates the worst compound.

SA3

EC-AMT

EC-Tyrosine

N4-AMT

N4-Tyrosine

Blood Clearance

2

4

3

1

Biodistribution

2

3

1

3

Planar Imaging (breast cancer model)

1

2

4

2

Planar Imaging (in vivo blocking)

1

2

1

3

Planar Imaging (breast cancer vs. inflammation model)

4

1

2

3

1

3

2

3

Conclusions
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IV.

Conclusions and Future Directions
In conclusion, four tyrosine and AMT-based precursors have been successfully

synthesized and radiolabeled with

99m

Tc. Table 6.7 summarizes the final

conclusions of the whole project. Base on the score system, we conclude that
99m

Tc-EC-AMT is the most suitable radiotracer for breast cancer imaging overall,

however,

99m

Tc-EC-Tyrosine will be a more preferential choice for differential

diagnosis of tumor from inflammation.
In the future, we will use

99m

Tc-EC-Tyrosine to evaluate the treatment

response of anti-cancer drugs or radiation therapy since it showed impressive
capability to distinguish the actual tumors from treatment-induced inflammation. In
addition, we will label these four precursors with gallium-68 and investigate their
imaging potentials in breast cancer imaging using PET or PET/CT. Furthermore, we
would like to label precursor EC-AMT with therapeutic radioisotope rhenium-188 or
yttrium-90 for cancer treatment given its high tumor accumulation (tumor %ID) and
T/M ratios.
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Table 6.7. Final conclusions of the dissertation. Score 1 indicates the best compound,
and score 4 indicates the worst compound.

SA1

EC-AMT

EC-Tyrosine

N4-AMT

N4-Tyrosine

Precursor Synthesis

3

1

4

2

99m Tc

Labeling

1

1

2

2

Partition Coefficient

1

3

2

4

Uptake Kinetics

1

3

2

4

Competitive Inhibition using L-Tyrosine

1

1

2

3

Blood Clearance

2

4

3

1

Biodistribution

2

3

1

3

Planar Imaging (breast cancer model)

1

2

4

2

Planar Imaging (in vivo blocking)

1

2

1

3

Planar Imaging (breast cancer vs. inflammation model)

4

1

2

3

1

2

3

4

SA2

SA3

Conclusions
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